https://www.pharmaradar360.com hourly 1 https://www.pharmaradar360.com/news hourly 0.95 https://www.pharmaradar360.com/regulators daily 0.9 https://www.pharmaradar360.com/trials daily 0.85 https://www.pharmaradar360.com/pipeline daily 0.9 https://www.pharmaradar360.com/drug-approvals daily 0.9 https://www.pharmaradar360.com/journals weekly 0.8 https://www.pharmaradar360.com/pharma-companies weekly 0.8 https://www.pharmaradar360.com/specialties weekly 0.8 https://www.pharmaradar360.com/sources weekly 0.8 https://www.pharmaradar360.com/newsrooms weekly 0.8 https://www.pharmaradar360.com/pharma-tools weekly 0.8 https://www.pharmaradar360.com/pharma-communities weekly 0.75 https://www.pharmaradar360.com/pro weekly 0.75 https://www.pharmaradar360.com/tools weekly 0.7 https://www.pharmaradar360.com/about monthly 0.5 https://www.pharmaradar360.com/privacy yearly 0.35 https://www.pharmaradar360.com/support monthly 0.35 https://www.pharmaradar360.com/disclaimer yearly 0.35 https://www.pharmaradar360.com/drug/pembrolizumab daily 0.9 https://www.pharmaradar360.com/drug/semaglutide daily 0.9 https://www.pharmaradar360.com/drug/tirzepatide daily 0.9 https://www.pharmaradar360.com/drug/trastuzumab-deruxtecan daily 0.9 https://www.pharmaradar360.com/drug/osimertinib daily 0.9 https://www.pharmaradar360.com/drug/nivolumab daily 0.9 https://www.pharmaradar360.com/drug/dupilumab daily 0.9 https://www.pharmaradar360.com/drug/risankizumab daily 0.9 https://www.pharmaradar360.com/drug/lecanemab daily 0.9 https://www.pharmaradar360.com/drug/atezolizumab daily 0.9 https://www.pharmaradar360.com/article/short-term-efficacy-of-tegoprazan-compared-with-esomeprazole-in-patients-with-no-52cea9f1e59c7bc3 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/proposals-for-individually-safe-and-realistic-correction-of-antipsychotics-in-ho-05a9f8821c95edf5 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-of-a-rubric-for-assessing-essential-basic-social-skills-required-at-0a0ac5300f3dfbc9 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-evaluation-of-reduced-dose-versus-standard-dose-remdesivir-in-patients-65b51af77de0a252 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/characteristics-of-medication-errors-prevented-by-community-pharmacists-during-t-8fd3fea7f73d36c4 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmacist-secondment-implementation-of-ward-based-pharmaceutical-services-and-c-c92b42fe2d16eb49 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/continuous-intervention-by-an-antimicrobial-stewardship-pharmacist-contributes-t-046de463fe7b026c 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/identification-of-risk-factors-for-lithium-associated-renal-impairment-a-multice-5f41a254316a4f7a 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluation-of-treatment-continuation-and-tolerability-using-the-urine-protein-to-7d9c0f2639c5f082 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/implementation-of-the-electronic-tracing-report-system-and-evaluation-of-its-use-71b92bcdcc397e3b 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/larval-density-development-and-distribution-of-costelytra-giveni-in-a-first-year-dfa5c9918d6a640a 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/indications-of-a-dependent-invention-for-the-use-of-which-a-compulsory-license-m-090bbb27c034b7e9 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/procedural-and-clinical-outcomes-of-second-generation-robotic-assisted-versus-ma-2ff0a102943ed8cd 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cardiac-troponin-in-pediatric-cardiology-toward-standardized-interpretive-framew-c21aedff40641d2d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-comparative-evaluation-of-p-tau217-stability-in-serum-and-plasma-using-two-val-e3b099e3c956cdd5 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/din-spec-91532-a-process-oriented-framework-for-quality-assurance-in-clinical-ma-af7479e9fd68713e 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-factors-related-to-cardiac-conduction-disturbance-in-patients-with-wild-1960f220eca28d40 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-impact-of-hospital-associated-disability-in-patients-with-acute-decompe-5990a34ce35f7358 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/high-intensity-statins-and-the-post-discharge-clinical-outcomes-at-1-year-after-6772e5c513209aca 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/endomyocardial-biopsy-and-clinical-outcomes-in-acute-myocarditis-multicenter-coh-ad26290eeb8a3c67 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/detection-of-crystalline-ibuprofen-components-in-ibuprofen-loaded-sba-15-mesopor-7138db2e1588d3b6 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluation-of-water-related-lt-i-gt-t-lt-i-gt-lt-sub-gt-2-lt-sub-gt-relaxation-b-0d37b85783605e80 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/exploring-the-therapeutic-impact-of-targeting-brk-in-epithelial-derived-cancer-c-de1a23859be6977e 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/realgar-transforming-solution-triggers-ferroptosis-associated-death-in-nb4-leuke-a1c5b8ee91dfa235 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/critical-medicines-lists-in-japan-and-the-european-union-insights-into-supply-re-b3c63434f9bb8e7d 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hydrophobic-compounds-in-the-lt-i-gt-paeonia-suffruticosa-lt-i-gt-root-cortex-re-fcc2875b79003b62 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/153abr-clinical-procedure-applications-d0e4148b0fd3773b 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/erratum-safety-tolerability-and-antitumor-activity-of-zipalertinib-among-patient-9348373953769dba 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/erratum-efficacy-and-safety-of-anselamimab-in-immunoglobulin-light-chain-amyloid-94141529a1094132 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/therapy-for-stage-iv-non-small-cell-lung-cancer-with-driver-alterations-asco-liv-959d85f1292c4974 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/reply-to-role-of-risk-reducing-bilateral-mastectomy-in-i-brca1-i-and-i-brca2-i-p-775da0d78d9dcbd0 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/reply-to-olaparib-in-metastatic-breast-cancer-the-impact-of-prior-cyclin-depende-d2c1227aecb440ba 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/intismeran-autogene-plus-pembrolizumab-versus-pembrolizumab-alone-in-high-risk-r-d4126ebab8f61724 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/he-was-always-there-f0fcbcf89c659ca0 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/olaparib-in-metastatic-breast-cancer-the-impact-of-prior-cyclin-dependent-kinase-df42a6f811bc75a6 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/combi-i-long-term-overall-survival-with-spartalizumab-plus-dabrafenib-and-tramet-952659f5b36f2fcf 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/role-of-risk-reducing-bilateral-mastectomy-in-i-brca1-i-and-i-brca2-i-pathogenic-82dafac178eac60b 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/developing-a-histology-based-artificial-intelligence-biomarker-to-predict-adjuva-7a52e5237fb6ed1f 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/should-artificial-intelligence-direct-systemic-therapy-decisions-in-pancreatic-c-c4a0a33b2312faed 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sustaining-high-reliability-amid-artificial-intelligence-adoption-in-oncology-593d81fb37071e65 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/oncology-drug-development-challenges-of-increasingly-available-therapies-ca545af2dd113f6f 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/impact-of-tumor-genomic-profile-on-adjuvant-chemotherapy-efficacy-in-resected-pa-3334b8a840da9cbe 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-and-validation-of-a-computational-histology-artificial-intelligence-ea25f506da3e0dd0 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/phase-ii-clinical-study-of-adebrelimab-and-bevacizumab-combined-with-cisplatin-c-c6e26ef3d70cbaea 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/magrolimab-plus-azacitidine-versus-placebo-plus-azacitidine-in-patients-with-unt-f50f60a602c26239 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-influence-of-social-media-on-users-intention-to-participate-in-clinical-tria-e5c75968b8839648 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/price-gouging-in-the-b2b-pharmaceutical-market-a-systematic-review-of-unethical-c525db114cfe942a 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hypnosis-for-postoperative-pain-management-following-colectomies-a-single-center-2399ea4259a39d8e 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/when-fear-became-the-barrier-to-care-lessons-of-a-clinical-rapid-response-during-40975bffd5c0cbd9 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-virtual-reality-cardiopulmonary-bypass-simulator-versus-conventional-halstedia-ac64a873d60ef83c 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/differential-detection-of-tau-aggregation-species-using-a-small-molecule-probe-f-d66e0f055a747884 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/an-explainable-ai-framework-for-early-mental-health-screening-and-clinical-decis-d1bcabc444546af5 2026-09-10T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hanmi-pharmaceutical-target-price-raised-to-650-000-as-roche-deal-value-reflecte-7b981f6d3cd04d61 2026-09-09T23:35:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-rare-after-aspire-miss-and-genglycos-win-has-valuation-3ffec4f293a82118 2026-09-09T23:28:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/portage-biotech-alp-financials-2026-income-statement-and-balance-sheet-alp-a532834d0e460662 2026-09-09T23:15:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/rebuilding-mexico-s-pharmaceutical-supply-chain-3e5a86b66630a924 2026-09-09T22:42:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-company-expanding-adding-jobs-in-hauppauge-d80f5da0a5cd0868 2026-09-09T22:30:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/louisiana-ag-takes-fda-and-pharmaceutical-companies-to-court-over-abortion-pills-2bbc103d0de45256 2026-09-09T21:46:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/hhs-names-four-senior-fda-officials-in-leadership-reorganization-54cf11cc363bef01 2026-09-09T21:34:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/generation-park-is-creating-a-national-pharmaceutical-hub-in-houston-bba29ce5588183be 2026-09-09T21:10:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/meet-annalina-che-the-scientist-behind-biotech-start-up-darkfin-labs-c8d101f77eaedcec 2026-09-09T20:08:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/seismic-pharmaceuticals-commences-global-phase-3-trial-of-istaroxime-in-patients-08ecec56915041b8 2026-09-09T20:05:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/technology-transfer-success-drivers-and-obstacles-explained-f93565e6205cc9ff 2026-09-09T19:36:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/kelun-biotech-s-twice-yearly-asthma-candidate-skb378-advances-into-phase-iii-c198555d2578e70f 2026-09-09T18:35:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-appeals-court-skeptical-of-bid-to-curtail-abortion-pill-access-6e050300f86774f7 2026-09-09T18:31:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/nueva-convocatoria-para-realizar-practicas-preprofesionales-0a0fa80b13f1b170 2026-09-09T18:20:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/u-s-and-tunisian-officials-break-ground-on-renovation-of-ministry-of-health-phar-ba2e86b24a145546 2026-09-09T18:19:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/leukemia-drug-data-suggested-a-different-way-to-treat-diabetes-a-new-biotech-wil-951cf12440ea5591 2026-09-09T17:57:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/cualtos-opens-registration-for-the-bachelor-s-degree-in-pharmaceutical-chemistry-cd37687b38cd07c5 2026-09-09T17:22:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/news-today-satya-niketan-collapse-a-wake-up-call-to-act-but-why-wait-for-tragedi-9e4d71030a910565 2026-09-09T16:37:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharma-s-r-d-commercial-approach-shifts-amid-global-policy-evolution-65d9e6dd72fa76dc 2026-09-09T16:35:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-fluidics-releases-upgraded-degasi-inline-degasser-range-147cc76d79d3987c 2026-09-09T16:32:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-firm-uses-space-to-help-cells-regenerate-bodily-structures-12b843a0aabf818f 2026-09-09T16:21:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/alpha-genesis-backs-biotech-startups-with-50m-agi-ventures-fund-99f88ef051673c6f 2026-09-09T16:19:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/eu-court-adviser-backs-challenge-to-pharmaceutical-wastewater-charges-f5177be301b558f1 2026-09-09T16:15:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/kura-spins-diabetes-work-into-a-lilly-backed-biotech-startup-ee94fc840173114d 2026-09-09T16:14:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-stocks-to-consider-september-9th-b898d2190cfcaabb 2026-09-09T16:07:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/ima-group-to-showcase-all-in-one-solutions-at-cphi-milan-8f37948273925931 2026-09-09T16:06:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/faq-inside-the-latest-mfn-deals-signed-by-nine-drugmakers-03b08aa8809af0e0 2026-09-09T16:03:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/four-biotech-stories-heating-up-right-now-f51da81af50695d6 2026-09-09T15:55:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-fills-four-senior-roles-including-top-officials-for-drugs-vaccines-and-tobac-12068fd76e56966c 2026-09-09T15:55:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-promoting-visiting-impact-assessment-8e5c43f577238ed7 2026-09-09T15:46:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/veraxa-biotech-designates-raju-willener-as-cfo-801ec29de9a56a5a 2026-09-09T15:46:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-medical-device-licensing-regime-impact-assessment-27313ede92bd836d 2026-09-09T15:46:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-050bf26e4894b2ca 2026-09-09T15:46:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-mhra-reforms-impact-assessments-d4da977182c6d068 2026-09-09T15:46:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-changes-to-pharmacy-appeals-process-impact-assessment-a5f9700a9414e0ed 2026-09-09T15:46:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-changes-to-section-75-of-nhs-act-2006-impact-assessment-5f9809bc31c7871f 2026-09-09T15:46:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-patient-safety-measures-impact-assessments-092abe2dadcce996 2026-09-09T15:46:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-role-and-functions-of-the-restructured-dhsc-fact-sheet-89c454d704f2bab3 2026-09-09T15:46:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-structural-measures-to-icbs-and-foundation-trusts-impact-assessments-7a34cf0996abe91d 2026-09-09T15:46:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-providers-fact-sheet-ad8fa072da7a9f6e 2026-09-09T15:46:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-icbs-as-strategic-commissioners-fact-sheet-6de16d25a204e1ef 2026-09-09T15:46:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-abolishing-nhs-england-impact-assessment-00de0de68dc58510 2026-09-09T15:45:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-icbs-as-strategic-commissioners-equality-impact-assessment-61dc9515198e3cd9 2026-09-09T15:45:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-impact-assessments-summary-744fa7c4f88e3806 2026-09-09T15:45:53.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-abolishing-nhs-england-equality-impact-assessment-a15632314deab107 2026-09-09T15:45:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-equality-impact-assessments-summary-8eeb40343ce210f9 2026-09-09T15:45:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/wall-street-weighs-impact-on-dyn-stock-post-novartis-phase-3-failure-rbc-says-th-ab7d5395de69c328 2026-09-09T15:41:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-promoting-visiting-equality-impact-assessment-33c1a8f7b32a87b9 2026-09-09T15:40:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-bill-medicines-and-medical-devices-regulatory-reforms-fact-sheet-7269b5ea8e00e2df 2026-09-09T15:40:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-s-del-desiran-misses-primary-endpoint-in-phase-3-dm1-trial-99ce4a179960b851 2026-09-09T15:31:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-the-biggest-ndc-12-risk-sits-in-the-handoffs-3d5e69a55011a8ea 2026-09-09T15:23:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/decision-medical-devices-given-exceptional-use-authorisations-bea04f575ed28a14 2026-09-09T15:08:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/federal-appeals-court-hears-baseless-challenge-to-the-abortion-pill-mifepristone-940486b7c14cf63f 2026-09-09T14:56:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/beeline-medicines-19dae1080a3df20c 2026-09-09T14:52:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-account-teams-call-claimguardrx-their-smartest-teammate-24ca28a696436c27 2026-09-09T14:24:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-proprietary-llm-behind-claimguardrx-s-detect-and-respond-engine-756b5ec033050dc5 2026-09-09T14:24:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/kura-creates-lilly-backed-spinout-armed-with-50m-to-advance-next-gen-diabetes-th-f97b4a180f77d74c 2026-09-09T14:20:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/macrogenics-inexpensive-adc-tce-biotech-with-multiple-catalysts-ahead-nasdaq-mgn-3992c5961012659d 2026-09-09T14:15:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/ideaya-biosciences-doses-first-patient-in-phase-3-trial-d00198a17e0c725f 2026-09-09T14:10:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/leerink-partners-initiates-coverage-on-teva-pharmaceutical-industries-nyse-teva-b4f76e98ec172cbd 2026-09-09T14:08:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-transition-to-home-why-confidence-is-critical-to-patient-success-f53fe705f45b7442 2026-09-09T13:58:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/matica-bio-bondwell-partner-on-texas-biotech-d0f4351f2a06e4f3 2026-09-09T13:56:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/trump-order-directs-federal-push-on-psychedelic-drug-research-and-review-7a02808d8f427079 2026-09-09T13:48:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/acrp-launches-2026-27-scholarship-and-grant-application-season-4a9b54371cfd920f 2026-09-09T13:45:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/orexin-discoverers-awarded-prestigious-lasker-award-0889c17faef35301 2026-09-09T13:43:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/luma-locks-down-15-year-410m-fund-for-life-science-investments-2229e6c1a7656df9 2026-09-09T13:43:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/field-safety-notices-31-august-to-4-september-2026-4fbb5b1daae2c350 2026-09-09T13:41:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/nutriband-ceo-gareth-sheridan-to-attend-inaugural-nasdaq-lab-biotech-summit-1307e17da858ae68 2026-09-09T13:31:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/tyra-rolls-toward-pivotal-cancer-study-even-as-stock-deflates-06453e4e0f97fa39 2026-09-09T13:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/five-years-at-bio-mexico-gaining-ground-in-global-biotech-ec0a6f6068da0a75 2026-09-09T13:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/guggenheim-reveals-top-biotech-stock-after-positive-clinical-trial-data-c106ca309e8a6793 2026-09-09T13:09:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/ocugen-doses-first-patient-in-phase-3-ga-gene-therapy-trial-32970696c462f25b 2026-09-09T13:06:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/decision-human-medicines-register-of-electronic-export-certificates-734f447a25d821db 2026-09-09T13:03:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/viral-haemorrhagic-fever-acdp-algorithm-and-guidance-on-management-of-patients-a442005e4b179daf 2026-09-09T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/impact-biotech-announces-completion-of-treatment-in-phase-3-enlighted-trial-of-p-39acc0eee159b7fc 2026-09-09T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/suddenly-this-summer-biotech-breaks-open-with-drug-approvals-ipos-will-it-last-25bef14c1bde5876 2026-09-09T12:57:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/decision-suspended-and-revoked-licences-and-registrations-for-manufacturers-and-258d162076f199f0 2026-09-09T12:42:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/nordic-biotech-ceos-reveal-secret-to-major-funding-and-pharma-deals-a3efea1f52140818 2026-09-09T12:37:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/don-t-ignore-the-insider-selling-in-biomarin-pharmaceutical-c392d2b0a526d595 2026-09-09T12:36:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/nitrosamines-from-detection-to-understanding-c0e645b8909bb3aa 2026-09-09T12:36:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/anmat-dispuso-la-baja-de-habilitacion-de-la-firma-rehue-s-a-y-prohibio-sus-produ-95c8696ba780c6c0 2026-09-09T12:32:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmasource-podcast-how-exoz-is-running-a-10-cdmo-rfp-for-cdmo-selection-3a007b19e8cf1ab3 2026-09-09T12:31:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-paid-pilot-will-test-trinity-biotech-cooling-fluids-in-ai-data-centers-7fd633709f73fc8c 2026-09-09T12:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/over-1-5-billion-to-help-nhs-withstand-year-round-pressure-cbf84c3935b064e9 2026-09-09T12:26:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-narcolepsy-drug-showed-median-reductions-of-up-to-88-8-in-sudden-muscle-loss-a-0ff7d04798652a97 2026-09-09T12:24:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/quarterly-epidemiological-commentary-mandatory-mrsa-mssa-and-gram-negative-bacte-bfc75e0710215140 2026-09-09T12:22:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-35523ec4937619f8 2026-09-09T12:13:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/atmospheric-nox-may-contribute-to-ndsri-formation-study-shows-717a069d3a62c417 2026-09-09T12:12:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-back-to-back-phase-3-failures-for-pelacarsen-and-del-desiran-send-share-2bac2be2f578a969 2026-09-09T12:10:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/world-health-expo-to-showcase-trillion-dollar-growth-across-pharma-biotech-longe-6803da287ace71b1 2026-09-09T12:07:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-may-2e45bd7b86003737 2026-09-09T12:06:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-apri-b7f6f80136a72c29 2026-09-09T12:06:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-marc-a9688d88c3a30590 2026-09-09T12:05:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-febr-df1ca0002f7ddc6b 2026-09-09T12:05:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-june-a0324311fd4d4714 2026-09-09T12:05:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-july-e4a658a591d9a33e 2026-09-09T12:04:56.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-augu-e29136a0758c031f 2026-09-09T12:04:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-sept-dd9b886471b7e27e 2026-09-09T12:04:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-octo-63ff575955c0b169 2026-09-09T12:04:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-janu-6665f6d4d545e2ad 2026-09-09T12:03:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-dece-b514e806327cec75 2026-09-09T12:03:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-nove-9bc61a228a7791a8 2026-09-09T12:03:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-octo-b016e524e13c6091 2026-09-09T12:02:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-sept-700ae1d4dc61471f 2026-09-09T12:01:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-3-f66515bf33b9f262 2026-09-09T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/three-chugai-researchers-behind-the-discovery-of-hemlibra-for-hemophilia-a-recei-818232e0bd38792c 2026-09-09T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/veradius-unity-and-bv-pulsera-mobile-c-arm-system-9in-and-12in-versions-0cb1d977b3032a6a 2026-09-09T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/philips-ingenia-achieva-and-intera-mr-systems-b7e6009e9e3fb961 2026-09-09T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/court-of-appeals-hears-oral-arguments-in-louisiana-abortion-pill-lawsuit-50fa9321f5302288 2026-09-09T11:50:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/ganesh-chaturthi-2026-mumbai-s-12-000-ganesh-mandals-under-fda-scanner-over-pras-be7950d397f186f7 2026-09-09T11:27:31.000Z weekly 0.7 https://www.pharmaradar360.com/article/mirum-pharmaceuticals-hires-lmh-strategic-solutions-284e103ab1270aa8 2026-09-09T11:24:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/decision-advertising-investigations-august-2026-0b95edb50287d7e6 2026-09-09T11:23:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/article-141-1-procedure-quarter-based-selective-dry-cow-therapy-dc21887708f5021b 2026-09-09T11:22:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/141-1-7a946e163c61ea87 2026-09-09T11:20:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/meningococcal-disease-guidance-data-and-analysis-cf4d903cf180377a 2026-09-09T11:16:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/adult-social-care-client-level-data-england-quarterly-update-to-june-2027-bab1705385315cda 2026-09-09T11:15:47.000Z weekly 0.7 https://www.pharmaradar360.com/article/adult-social-care-client-level-data-england-quarterly-update-to-september-2026-404dfd4156db3fd3 2026-09-09T11:15:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/opus-genetics-announces-positive-low-dose-cohort-1-data-from-phase-1-2-clinical-9da1ba6971e41fb4 2026-09-09T11:06:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/kane-biotech-to-host-commercial-update-webcast-on-september-16-9a8886880a182539 2026-09-09T11:05:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/algorithmic-tool-may-improve-screening-of-patients-for-an-alzheimer-s-clinical-t-562efba4ceb9605d 2026-09-09T11:00:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-is-still-reviewing-rezolute-s-experimental-drug-no-timeline-is-set-cf406d8464aac8e4 2026-09-09T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/beeline-flies-into-ph-3-as-oral-lupus-drug-soars-past-placebo-303874c2252c60b3 2026-09-09T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/exclusive-cancer-biotech-twostep-gets-62-5m-to-take-twist-on-adcs-into-clinic-817e254766ff52c2 2026-09-09T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/matica-biotechnology-and-bondwell-technologies-collaborate-to-advance-texas-biot-0849105330920f96 2026-09-09T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/schrodinger-births-new-immunology-and-inflammation-biotech-tectora-therapeutics-3c2ecfcd5bb63fb8 2026-09-09T10:58:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/solstice-rises-with-225m-series-a-to-advance-next-gen-ctla-4-immunotherapy-into-398cbf270d73588b 2026-09-09T10:58:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-manufacturing-questions-facing-chinese-biotech-cf50d2874a8599be 2026-09-09T10:56:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/moonwalk-banks-70m-to-progress-sirna-therapy-for-obesity-de269d2e1175ff14 2026-09-09T10:50:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/unparalleled-opportunity-sandoz-embarks-on-ambitious-biosimilar-growth-strategy-676c4323204a4fcf 2026-09-09T10:49:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/mannkind-and-rose-pharma-inc-enter-licensing-and-collaboration-agreement-to-deve-9e7da1cb20ba16a8 2026-09-09T10:46:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-rapid-acting-short-duration-inhaled-treatment-is-being-developed-for-weight-ma-e383768e6e897a31 2026-09-09T10:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/guidance-medicines-that-you-cannot-export-from-the-uk-or-hoard-6902f574353aeb80 2026-09-09T10:28:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-makes-pharmaceutical-speaker-programs-illegal-f87d152b9ae8d979 2026-09-09T10:10:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-global-eye-cancer-trial-has-dosed-its-first-patient-529d4d314833481c 2026-09-09T10:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biden-era-abortion-by-mail-rules-face-key-test-at-appeals-court-hearing-0cd9e746f1b92012 2026-09-09T10:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nafdac-and-nhrec-announce-new-dates-for-mandatory-stakeholders-training-on-clini-c75adb4ff13bd3af 2026-09-09T09:53:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-among-independent-f32c88a42723b612 2026-09-09T09:50:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/ebola-disease-information-sheet-for-category-4-returnees-from-an-ebola-affected-3451106449dc4cbd 2026-09-09T08:30:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/ebola-disease-information-sheet-for-category-3-returnees-from-an-ebola-affected-66d6f6455dcf6d66 2026-09-09T08:30:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/ebola-disease-information-sheet-for-category-2-returnees-from-an-ebola-affected-0ad9eb86ec575c6f 2026-09-09T08:30:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/ebola-disease-information-sheet-for-category-1-returnees-from-an-ebola-affected-24c7b8b02c106176 2026-09-09T08:30:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/ebola-and-marburg-contact-matrix-for-returning-workers-scheme-and-non-uk-exposur-dedb115fc574e9fe 2026-09-09T08:30:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/ebola-virus-disease-clinical-management-and-guidance-74343e283fe62dbc 2026-09-09T08:30:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/ebola-returning-workers-scheme-public-health-advice-3f98a3a732b6c31c 2026-09-09T08:30:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/barclays-upgrades-sagimet-stock-rating-on-acne-drug-potential-ae3e9d55d7da7baa 2026-09-09T08:08:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/oral-infigratinib-shows-meaningful-benefits-beyond-growth-within-52-weeks-in-chi-0c539f69c1cd457c 2026-09-09T08:04:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-sleep-apnea-measure-rose-10-4-with-an-experimental-drug-versus-49-2-with-place-90e8edbb76843343 2026-09-09T08:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/mosliciguat-advances-to-phase-3-phrontier-trial-after-phocus-study-shows-20-pvr-7689bcdaf1ae338a 2026-09-09T07:34:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/medicine-shortages-grow-in-iran-as-us-tightens-sanctions-blockade-ecd987fe722f5a4e 2026-09-09T07:20:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/maharashtra-fda-cracks-down-on-food-safety-violators-5fff85b007469683 2026-09-09T06:07:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/maharashtra-fda-suspends-food-licenses-of-railway-catering-supplier-20-eateries-c5fd85665f97fc76 2026-09-09T06:02:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/steady-stream-of-crossover-rounds-stock-biotech-s-ipo-pipeline-dbbe4746af7c54ed 2026-09-09T04:17:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/ibento-ibento-report-on-the-pmda-hokuriku-branch-10th-anniversary-symposium-c1a0e57e7ec099d8 2026-09-09T03:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/taiwan-s-obigen-pharma-to-unblind-phase-3-botox-trial-early-in-november-year-end-af705b30fbefc4cc 2026-09-09T02:26:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/wegovy-and-mounjaro-for-weight-loss-not-funded-a2a3ffb1738d2e00 2026-09-09T02:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/many-different-paths-may-lead-to-a-role-in-clinical-project-management-96598feaeb50c516 2026-09-09T00:39:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/click-e-stock-one-novartis-new-drug-fails-phase-3-target-price-for-alteogen-lowe-7cafc5a1c226a35d 2026-09-09T00:23:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/novo-nordisk-filed-form-6-k-9e8f3bd2a58b229c 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gsk-filed-form-6-k-0a518003195b02c6 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-e335cd1b22d70e1f 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-9aa625139ac75227 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-1e47573291afd54f 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-8eb3d6242be7cf81 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-930c63ad0185a524 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-e89a231cfd924a47 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-a78f64ffb4d5c5bc 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-f72c07194289862e 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-4c8b30d98486094c 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-326f5ae30be376d1 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-a5ee3eb788954281 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-24899144f167d31e 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-20eab0fecbf9a929 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/home-page-385c389d5cd84eee 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/temporary-policies-for-compounding-certain-starter-parenteral-nutrition-drug-pro-bff9d18f307f05a1 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/vaccines-and-related-biological-products-advisory-committee-notice-of-meeting-es-b6fb3f98dd33049b 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-hum-9e81e95c6000ebb0 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/privacy-act-of-1974-system-of-records-99f349f787d2f97e 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/determination-of-regulatory-review-period-for-purposes-of-patent-extension-andem-d38ea0d42ee8ba36 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-pre-8f9c9e790ba2b6a8 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/determination-of-regulatory-review-period-for-purposes-of-patent-extension-anzup-eeb61cd6a595bf0b 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ankti-9840243fd9e98d18 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-vaccine-injury-compensation-program-list-of-petitions-received-bee1e53401727a8f 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/reorganization-of-the-national-center-for-immunization-and-respiratory-diseases-588d95ecfd03eea8 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/tips-for-dealing-with-empty-nest-syndrome-64aa3c260d31a871 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cleveland-clinic-partners-with-luminai-to-transform-health-system-operations-8b1951904a6aedef 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/beyond-70-000-reassessing-the-global-fontan-population-through-citation-chain-an-b1ba1fb432aad77c 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/neo-adjuvant-approvals-for-solid-tumors-by-the-us-food-and-drug-administration-2-756ed3abf614efc6 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-phase-3-trial-of-vosoritide-in-children-with-hypochondroplasia-6de4f09ea4b05915 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/association-of-i-helicobacter-pylori-i-infection-with-insulin-resistance-tumor-n-316790c378779761 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/phenomenology-in-pediatric-nursing-lessons-from-studies-of-mothers-caring-for-ch-4f3fffea388d6bfe 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/utilizing-a-smartphone-application-for-perinatal-depression-screening-and-care-l-d1657f9c0ce56b10 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/network-biology-to-artificial-intelligence-building-the-next-generation-of-predi-7049814c4b1b0ea9 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/interactions-of-nanoparticles-with-structures-of-the-respiratory-system-nanopart-6e7d20d5c4593f8d 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/inhaled-nanoliposomes-for-treating-lung-disease-including-a-case-study-of-amikac-5c581901e1fef964 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-delivering-particles-aim-to-breach-the-blood-brain-barrier-6b0773077796d0f1 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/mechanical-basis-of-cortical-cataract-214599f9167e95ce 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07811128-leveraging-digital-health-solutions-to-collect-patient-reported-outc-de9c163ffaa5b58e 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07810855-using-bedside-ultrasound-to-understand-fluid-management-in-patients-f01e5454fd815262 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07810231-prospective-longitudinal-cohort-study-of-implant-age-pocket-plane-in-f1335f5a7fd090e7 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07809542-brain-network-characteristics-of-pain-patients-based-on-magnetoencep-f1102e08355c2f4a 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07809438-a-comparative-performance-study-between-high-and-standard-resolution-a7b9283bcd325474 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07809399-volumetric-hrct-in-stable-copd-patients-905336f1346cda49 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07809087-feasibility-study-of-an-interactive-wall-based-intervention-program-68f2eb96ca9dbf6e 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07809074-mindfulness-and-self-compassion-intervention-for-ostomy-patients-due-928772f3ba63ee88 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07808645-wearable-sleep-eeg-and-auditory-stimulation-in-healthy-adults-a3f895f1435a9f4e 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07803471-yiqi-fumai-lyophilized-injection-for-chronic-heart-failure-caused-by-a2f07156d8dd8c5f 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07796373-nemtabrutinib-for-chronic-lymphocytic-leukemia-cll-small-lymphocytic-38cf1b9c433f4464 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07770919-continuous-theta-burst-stimulation-for-generalized-anxiety-disorder-a11ec2e143861103 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07755748-glaucoma-screening-to-enhance-at-risk-californians-health-survey-res-613aad5046be38a3 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07686380-il-15-superagonist-with-or-without-vaccine-in-biochemically-recurren-cfd5e39e4ab2fd00 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07668518-a-study-of-the-safety-tolerability-pharmacokinetics-and-efficacy-of-53495f0e626ad570 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07667400-docetaxel-and-sx-682-in-recurrent-metastatic-head-and-neck-squamous-eb782075b524b62c 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07645443-feel-good-a-multicenter-trial-of-a-mindfulness-based-group-therapy-i-e6b3a6106587bc2a 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07524530-stem-cell-transplantation-for-participants-with-germline-runx1-assoc-f7c7537ec91ee762 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07509034-autologous-b7-h3-chimeric-antigen-receptor-t-cells-in-previously-tre-2b314a9db8642130 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07447557-study-of-intrathecal-elp-02-for-charcot-marie-tooth-disease-type-4j-9df85b59b7760510 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07436728-a-study-of-tak-505-in-adults-with-solid-tumors-0ceaf12c08fe7644 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07262983-evaluating-the-safety-and-tolerability-of-baricitinib-in-patients-wi-834c49c5b61fdd2a 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07241377-a-study-in-healthy-adults-to-compare-the-bioavailability-of-epa-dha-04a145623e5fd712 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07234942-a-study-to-investigate-the-safety-tolerability-pharmacokinetics-and-934403a64baf19fb 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07224763-study-to-evaluate-the-safety-and-efficacy-of-the-ggta1-ko-thymokidne-e7469684f1a340a9 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07210398-mindfulness-based-cognitive-therapy-for-the-chronic-pain-early-cogni-a5c8ad0779df2ad7 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07205107-clindamycin-phosphate-adapalene-and-benzoyl-peroxide-triple-combinat-c2ef75272e264556 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07166094-study-to-assess-the-efficacy-and-safety-of-rina-s-compared-to-treatm-654bf6bd00153589 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07137442-distinguishing-tics-and-functional-tics-using-clinical-neurophysiolo-e0a0f7cc00953d72 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06851806-study-of-palivizumab-in-children-with-high-risk-of-severe-respirator-030ea64e3955972a 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06825702-safety-tolerability-and-efficacy-of-intravitreal-kio-104-in-patients-8d4299ce7f4765dc 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06782308-tinnitus-patient-preferences-survey-717b4fa3f14c3c2b 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06578520-effect-of-the-use-of-dapagliflozin-in-patients-with-refractory-heart-ed2d60e95fd26467 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06548412-ctx-009-with-gemcitabine-cisplatin-and-durvalumab-as-first-line-ther-2b2fdba90bbebbba 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06470048-a-clinical-study-to-evaluate-ianalumab-in-participants-with-diffuse-81b10aa4165bd17c 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06410248-triapine-in-combination-with-temozolomide-for-the-treatment-of-patie-0cf1d97b4e719323 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06323161-a-research-study-to-see-how-much-cagrisema-lowers-blood-sugar-and-bo-7b5290a15f28fde0 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06260228-home-based-self-management-and-cognitive-training-changes-lives-hobs-ff1e48edbb3a2369 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06235801-a-phase-i-ii-study-of-gilteritinib-and-momelotinib-for-patients-with-1fe17411a66cc840 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06052631-microneurographic-assessment-of-peripheral-nerves-in-healthy-volunte-19ef87b4db826563 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05713799-trial-of-the-combination-of-alpha-lipoic-acid-and-mirabegron-in-wome-58ca62d5ec6a8459 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05706558-retrospective-review-of-esophageal-cancer-at-mskcc-cafd4ee1a7b70879 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05570253-a-study-of-sdx-7320-in-combination-with-eribulin-for-people-with-bre-7c04db2a9102a2ce 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05232071-placebo-controlled-proof-of-concept-study-to-evaluate-the-safety-and-9fcfbde442103736 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05037461-precision-radiotherapy-using-mr-linac-for-pancreatic-neuroendocrine-fcedc2d84f591031 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04847648-air-polishing-in-the-treatment-of-peri-implantitis-7fadfb7a67b10d53 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04542824-trial-of-the-safety-and-efficacy-of-epcoritamab-in-japanese-subjects-8f8b2e5edddf7421 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04124497-a-trial-for-relapsed-and-relapsed-refractory-multiple-myeloma-patien-96886e54e668bcc6 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03625037-first-in-human-fih-trial-in-patients-with-relapsed-progressive-or-re-7c8817969428243d 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03549754-icareme-global-registry-multinational-real-world-evidence-in-cardior-ca8b38986b5aecf0 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct03307109-quality-of-life-in-patients-having-a-prosthetic-joint-infection-2572312124caf8f4 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct02890329-ipilimumab-and-decitabine-in-treating-patients-with-relapsed-or-refr-cc9d070597ff8255 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct02767011-tele-health-electronic-monitoring-to-reduce-post-discharge-complicat-c84b8d01820bce9e 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct01568658-genetic-and-physical-study-of-childhood-nerve-and-muscle-disorders-f16cdfe7ad322553 2026-09-09T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-trial-wins-sent-roivant-and-pharvaris-higher-98c19d328893c1ff 2026-09-08T23:38:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/as-fda-sets-ai-principles-for-drug-development-how-much-evidence-is-enough-a883e1c3fce040a0 2026-09-08T22:40:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/trump-administration-names-permanent-leaders-at-fda-amid-ongoing-controversies-b3c82c9c2a34e326 2026-09-08T22:38:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharvaris-stock-jumps-after-positive-hae-drug-t-4085528d18522778 2026-09-08T21:57:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/novo-nordisk-a-s-stock-nvo-closed-down-by-3-09-on-sep-8-facts-behind-the-movemen-bf3c0573fb832069 2026-09-08T20:15:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/hhs-announces-key-leadership-selections-at-fda-to-promote-innovation-reform-and-da223f20305656e3 2026-09-08T19:59:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/appeals-court-to-rule-soon-on-marijuana-rescheduling-as-billions-in-cannabis-tax-4dc1e47ad31e8837 2026-09-08T19:33:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/quantum-biopharma-s-lucid-ms-gets-fda-clearance-for-phase-2-trial-in-multiple-sc-6e1a50fab04737c7 2026-09-08T18:13:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/amgen-falls-10-as-novartis-trial-failure-clouds-a-cholesterol-drug-class-nvs-sto-577262ea46adae76 2026-09-08T17:08:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-suffers-third-clinical-setback-in-a-week-wiping-out-over-40-billion-in-aecba47d0f5a987e 2026-09-08T16:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-withdraws-publication-of-covid-shingles-vaccine-research-findings-0c9137b444e2e92a 2026-09-08T16:40:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/moderna-begins-phase-1-clinical-trial-of-ebola-vaccine-against-strain-behind-drc-0f15edae8af6e558 2026-09-08T16:36:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-a-cannabis-business-is-betting-on-dogs-to-reach-fda-approval-e63e12a392c30ad2 2026-09-08T16:29:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/pneumococcal-vaccination-for-older-adults-and-for-individuals-in-a-clinical-risk-a3c9fa73d91e326d 2026-09-08T15:28:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/house-advances-carter-s-bipartisan-bill-to-reduce-animal-testing-in-drug-develop-f90a2c9708224bfc 2026-09-08T15:28:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/maharashtra-fda-enforces-zero-tolerance-with-major-food-safety-crackdown-a0e97e5aa54ea452 2026-09-08T15:25:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/nuevos-proyectos-de-consulta-para-la-opinion-publica-f60c4dde925aa14a 2026-09-08T15:16:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/green-shoots-for-uk-pharma-investment-but-delivery-will-decide-whether-they-take-a66e726a10440e23 2026-09-08T14:47:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/ionis-pharmaceuticals-gets-85-price-target-des-88a596b142c0403e 2026-09-08T13:49:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/x4-pharma-gains-fda-agreement-to-cut-phase-3-trial-size-to-76-patients-86a2f6c69c45444e 2026-09-08T13:20:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/exozymes-selects-curia-as-commercial-scale-manufacturing-partner-for-nct-e32fe23efc672768 2026-09-08T13:05:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/imdelltra-in-combination-with-imfinzi-demonstrated-landmark-improvement-in-overa-2f50edcb3c7d5463 2026-09-08T13:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/mrsa-mssa-gram-negative-bacteraemia-and-cdi-monthly-data-2025-to-2026-46183ecdfec674cc 2026-09-08T12:46:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/annual-flu-programme-8d7750db1c23f662 2026-09-08T12:44:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/wegovy-for-overweight-young-children-novo-nordisk-s-obesity-drug-shows-effective-3431f97d0f9e3263 2026-09-08T12:30:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/vor-biopharma-vor-completes-enrollment-in-phase-3-trial-as-market-eyes-growth-po-6854d0a7bff59ab1 2026-09-08T12:18:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/enregistrement-des-antibiotiques-dans-vamreg-e-learning-pour-les-veterinaires-5fb5bf0d85ad7573 2026-09-08T12:16:55.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-12b-avidity-acquisition-hits-phase-3-speedbump-as-dystrophy-drug-disapp-81a38543b41b14c8 2026-09-08T12:12:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/xfor-gains-fda-nod-for-reduced-trial-size-in-pivotal-phase-3-study-dfe6bf454bee75c8 2026-09-08T12:10:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/tozorakimab-demonstrated-statistically-significant-and-highly-clinically-meaning-4a747bc53373c024 2026-09-08T11:45:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biovie-announces-next-stage-of-fda-engagement-for-phase-3-parkinson-s-disease-pr-86f2e64a80edb748 2026-09-08T11:41:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/artiva-biotherapeutics-announces-planned-2026-data-readouts-and-phase-3-trial-in-d72d6fed3e722f8c 2026-09-08T11:41:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nature-medicine-features-a-briacell-trial-among-11-shaping-medicine-in-2026-a2c3aef4540443f1 2026-09-08T11:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/biovie-seeks-fda-feedback-on-a-proposed-parkinson-s-trial-of-about-175-patients-ee88e950491954eb 2026-09-08T11:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/briacell-s-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-can-339c6a459d143c72 2026-09-08T11:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/oncologists-say-newly-approved-pancreatic-cancer-drug-is-a-breakthrough-for-trea-81381f05106e10cb 2026-09-08T11:26:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/okyo-pharma-nasdaq-okyo-readies-phase-3-trial-of-eye-pain-drug-urcosimod-90d050241783edad 2026-09-08T11:01:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-50-million-payment-is-coming-to-monte-rosa-as-novartis-starts-a-sjogren-s-tria-31715f4d196d2209 2026-09-08T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-new-trial-for-eye-related-muscle-weakness-is-planned-for-2027-vor-bio-finished-b45892b2c443c86f 2026-09-08T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bristol-myers-squibb-announces-positive-topline-results-from-registrational-phas-8624811f3ce076b9 2026-09-08T10:59:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/merck-to-participate-in-the-morgan-stanley-24th-annual-global-healthcare-confere-e76ae3336b1268bc 2026-09-08T10:45:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/vaccine-update-30d4e36f5ec7eb5a 2026-09-08T10:02:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/vaccine-update-issue-375-flu-special-2026-1a30d6fa07e93be8 2026-09-08T10:01:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/up-to-200-000-people-live-with-this-lung-disease-roivant-starts-a-new-trial-d037a53d1ec5911f 2026-09-08T10:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/tukaram-mundhe-s-fda-steps-up-drug-crackdown-in-maharashtra-complaints-jump-557-ecfe5acba6850e4a 2026-09-08T09:56:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-12bn-avidity-bet-falters-on-late-stage-del-desiran-flop-a07058258a6406e4 2026-09-08T09:51:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/2026-0170da8a7075e9e1 2026-09-08T09:40:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-heart-drug-fails-phase-3-trial-cutting-genetic-ch-0570ea9380fbcdd9 2026-09-08T09:39:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/2026-2b2822c02a7f5c39 2026-09-08T09:35:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/prac-d8971a24133f87f2 2026-09-08T09:07:37.000Z weekly 0.7 https://www.pharmaradar360.com/article/characteristics-of-people-infected-with-toxigenic-c-ulcerans-74755f86c69d844a 2026-09-08T08:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/ukhsa-evidence-reviews-8f54ff16e8d4cd78 2026-09-08T08:30:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/ame-bridge-management-1a3a141ab51144fc 2026-09-08T08:16:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharma-major-novartis-falls-10-after-three-drug-trial-setbacks-92f853f4d5272a6c 2026-09-08T07:51:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/upstream-bio-presents-results-from-the-phase-2-valiant-trial-of-verekitug-for-th-e4bacc39df389b5c 2026-09-08T07:40:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/upstream-bio-reports-phase-2-valiant-trial-results-showing-verekitug-reduced-sev-18afce1d16ed54f2 2026-09-08T07:40:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-stock-slides-as-centerpiece-of-12b-avidity-buyout-flunks-crucial-phase-369fe1ae5d30a5c0 2026-09-08T07:34:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/neuromuscular-drug-from-novartis-fails-in-key-study-adding-to-pressure-on-compan-7599cd1f8178910a 2026-09-08T07:31:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-quarterly-dose-cut-asthma-flare-ups-56-versus-a-dummy-treatment-upstream-bio-p-5957ae35a18b8b3f 2026-09-08T07:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/tukaram-mundhe-effect-100-days-12-083-actions-as-maharashtra-fda-leads-biggest-s-d98c23d18ab152bc 2026-09-08T06:42:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/food-safety-chief-tukaram-mundhe-s-plan-for-festivals-in-maharashtra-8c168d932d6ebed2 2026-09-08T05:32:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/newron-reports-subscription-for-eur-5-5-million-of-shares-by-investor-group-as-p-9cedb9c94f3df816 2026-09-08T05:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/what-data-says-about-tukaram-mundhe-s-100-day-stint-as-fda-commissioner-196f7cd7d48755cb 2026-09-08T04:03:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/bmc-medical-co-ltd-recalls-luna-g3-apap-model-lg3600-with-firmware-g3-2-00-76-du-49c4827bc368c793 2026-09-08T04:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/maharashtra-fda-inspections-expose-drug-safety-gaps-e2b63ad181bd692b 2026-09-08T03:20:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/yakkyokukata-jp-drafts-september-2026-part-1-posted-58fb2b9570d86ac0 2026-09-08T03:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/yakkyokukata-jp-drafts-september-2026-part-2-posted-7fc8f7827c7927a1 2026-09-08T03:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/astrazeneca-filed-form-6-k-3c9bb893b8f5ebb3 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gsk-filed-form-6-k-d43e989b55ee68c6 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-filed-form-6-k-9a3be5d9cea2290a 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/mark-allen-d-d-s-rescission-of-final-agency-action-and-withdrawal-of-order-to-sh-4ff464311d7f3296 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-public-comment-requ-ba5586ce8851a924 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/medicare-program-town-hall-meeting-on-the-fiscal-year-2028-applications-for-new-e0882cd256184bcf 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/proposed-data-collection-submitted-for-public-comment-and-recommendations-51525e15cfb1b3ee 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/center-for-scientific-review-amended-notice-of-meeting-945ea22744a88fc9 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bulk-manufacturer-of-controlled-substances-application-irvine-labs-inc-06b927a4afc4595e 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/importer-of-controlled-substances-application-fisher-clinical-services-inc-4f126cd097473cf8 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/importer-of-controlled-substances-application-cambrex-high-point-inc-e82f843236b1838a 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/importer-of-controlled-substances-application-fresenius-kabi-usa-llc-a380373346bbc5af 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/stephen-bossenberry-m-d-decision-and-order-a19b15ba4f04fad0 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/importer-of-controlled-substances-application-andersonbrecon-inc-dba-pci-pharma-58475345f958d070 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-33d1d408902e2bdd 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/submission-for-omb-review-30-day-comment-request-data-and-specimen-hub-dash-euni-43d65c3b310c33ea 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-unspecified-product-56f4aad8c780fb7f 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-baloom-2-panthenol-hydro-airy-sunscreen-76166a8e1258bb36 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/should-kids-have-mental-health-days-b366f95b902dfefd 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/united-therapeutics-corporation-announces-accelerated-share-repurchase-agreement-d3b6ea9ca8945a2a 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bausch-health-and-yun-announce-expansion-to-mexico-and-across-additional-emea-ma-f40b7d30c789ecd7 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pr-siliq-brodalumab-injection-now-reimbursed-under-alberta-s-public-drug-plan-im-e79ea40f76db38fd 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/outcome-definitions-in-clinical-trial-registrations-a-cross-sectional-study-80ea0dc761f2ea79 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/safety-pharmacokinetics-and-pharmacodynamics-of-the-glp-1-gip-gcg-receptor-agoni-732b3a954859f846 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/butylphthalide-combined-with-tenecteplase-in-mild-disabling-acute-ischaemic-stro-8632aa90834b8816 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/systematic-review-and-meta-analysis-of-intrathecal-drug-delivery-systems-for-the-78fe51bd2837a2ad 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/randomised-phase-iii-trials-of-cancer-prevention-drugs-a-systematic-review-and-p-e0ab6c687137bfcb 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-bayesian-phase-i-ii-trial-design-to-optimizing-dose-schedule-regimen-with-comp-2fe1ae9d0f6e2108 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-various-types-of-remineralizing-agents-on-the-remineralization-of-mild-6e735d880cd42199 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparison-of-microdrop-administration-using-a-bottle-adapter-of-2-5-phenylephri-1bd95ea7d3830788 2026-09-08T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/notifiable-diseases-causative-agents-reports-for-2026-32900b46450305d4 2026-09-07T15:38:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/medicines-eligible-for-northern-ireland-mhra-authorised-route-ea4846a98bf6c2a7 2026-09-07T14:03:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/only-around-half-of-primary-school-children-got-their-flu-vaccine-last-year-403f49a5bd04d397 2026-09-07T11:44:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/2-2026-3c227aa9e7354928 2026-09-07T11:21:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/tobacco-and-vapes-packaging-appearance-and-display-b0f65b22298b2fc9 2026-09-07T11:19:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/2026-a3d36d0f75424a9d 2026-09-07T11:11:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/mdd-class-i-ndi-passive-sphere-b7d0605889498eca 2026-09-07T10:03:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/tongkat-ali-honey-herbal-mixed-paste-1310aadc35d80ee8 2026-09-07T09:49:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-41-report-data-to-week-40-dat-57a8ff892a5702f4 2026-09-07T09:40:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-4-october-2026-3416de2db5fbba30 2026-09-07T09:40:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-european-joint-programme-on-rare-diseases-d53cc8321f2dea5f 2026-09-07T09:40:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-harmonised-approach-to-early-feasibility-studies-for-medical-devi-0fb60975f2bf9da6 2026-09-07T09:40:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-report-week-41-report-data-to-week-40-data-up-t-544b20cee08c6ce5 2026-09-07T09:32:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-healthy-adaptation-to-pregnancy-postpartum-and-parenthood-82c4989530fdfda2 2026-09-07T09:25:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-lpt-laser-based-proton-therapy-syslpt-laser-based-proton-therapy-6966003adb9cf5cc 2026-09-07T09:24:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/driving-digital-transformation-amanda-strydom-on-women-technology-and-leadership-b25e6893da42d72b 2026-09-07T09:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-protection-in-children-and-young-people-s-settings-including-education-cca215b8fd3fb49b 2026-09-07T08:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/amarin-group-esg-3-9-ftse-russell-ea572dc6a605d4a4 2026-09-07T07:35:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-37-report-data-to-week-36-dat-12867e0648495a43 2026-09-07T06:58:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/11-jbda-1e862f8e99770ad1 2026-09-07T06:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/research-achievement-related-to-chugai-originated-nemolizumab-receives-the-11th-698ca4f032fd30e5 2026-09-07T06:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-hand-sanitizer-vanilla-frosting-502a8098e1a85c7c 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-nadolol-9ecde2dfb8ab0283 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-american-safety-and-first-aid-triple-antibiotic-73419f5abf1f0e8e 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-american-safety-first-aid-a829d4721e66769d 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-lady-speed-stick-24-7-fresh-fusion-3cc457ca2f39b640 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-hydrating-mist-hand-sanitizer-with-silicone-keychain-holder-be-864d678e71f2b91f 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-medi-first-topical-analgesic-3c8148ed4f999e88 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-pain-relieving-lidocaine-patch-bf93f3783ab22813 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-candesartan-cilexetil-b916f82c8372ddec 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-mycophenolate-mofetil-b26da168ebd7aaa8 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-hydrating-mist-hand-sanitizer-with-silicone-keychain-holder-si-9ffe521131db9c95 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-hsenjt-arnica-bruise-cream-3f2dbcb573a9d9c2 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-hsenjt-antifungal-cream-b03d186973378fab 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-bzk-antiseptic-towelette-7757b41c536188cf 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-sting-relief-pad-b2fae5b78e3baa71 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-alcohol-prep-pads-medium-sterile-06e2f1ee977c552c 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-unspecified-product-3a33edb2c5e2a501 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-speed-stick-power-ultimate-sport-7bc931b75bd52c25 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-hand-sanitizer-cherry-sundae-d156d9e332eb3a64 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/survey-reveals-how-social-media-influences-men-s-health-pkg-329128b04c75c02f 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nanoparticle-based-strategies-to-enhance-psma-targeted-radioligand-therapy-a-rev-635a306c2914999f 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/integration-of-proteomic-aging-clocks-in-a-phase-2a-clinical-trial-supports-simu-7be6a31c09a0d1b6 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/salovum-reduces-mortality-in-isolated-severe-traumatic-brain-injury-a-randomized-f5280cc30cebfe6c 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/use-of-the-bacterial-lysate-om-85-for-the-primary-prevention-of-wheezing-lower-r-daaaa4b1cdcd0cc5 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/assessment-of-lebanese-community-pharmacists-perceptions-and-practices-towards-p-29b4dbe8992d3edd 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-antidepressant-effects-of-the-mglu2-3-receptor-antagonist-ts-161-in-treatmen-252e248060ef67c5 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/efficacy-and-safety-of-fixed-dose-combination-therapy-with-cilostazol-and-rosuva-6f26c99c15c20bdb 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/adjunctive-corticosteroids-in-herpes-simplex-virus-encephalitis-a-meta-analysis-e715ee16f58019ab 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/low-dose-ticagrelor-combined-with-aspirin-for-preventing-early-neurological-dete-8818d98d390612bd 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/selecting-vehicle-comparators-in-dry-eye-disease-clinical-trials-implications-fo-71d14de03c0ea035 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-randomized-controlled-trial-of-a-multimodality-digital-health-intervention-to-c65082810d3a9f7c 2026-09-07T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-noicaky-fungal-nail-patches-c59b3d0016266246 2026-09-06T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-skin-wart-remover-liquid-4a1fa90f63dc48d5 2026-09-06T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-inlifay-antifungal-1b0d8445adbc37b5 2026-09-06T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-label-update-versacloz-84957927c389ee11 2026-09-06T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-registry-based-perspective-of-interventional-clinical-trials-for-duchenne-musc-9f2fc0f042f3f538 2026-09-06T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/enhancing-evidence-generation-by-linking-randomized-clinical-trials-to-real-worl-5d94e8e18f9c4ad2 2026-09-06T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-invisible-to-enrolled-how-artificial-intelligence-is-reshaping-clinical-tri-53e62a54872a53c7 2026-09-06T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/regulatory-and-scientific-challenges-in-paediatric-oncology-d3b46ab83794e42f 2026-09-06T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-recasts-drug-packaging-oversight-with-science-and-risk-based-container-closu-212514b16ec9a406 2026-09-05T14:29:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/oric-stock-holds-steady-as-biotech-eyes-next-trial-and-earnings-0490ce6768597bd1 2026-09-05T14:15:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/vrxa-jumps-as-traders-focus-on-biotech-breakout-setup-ffe5bbb195e962d9 2026-09-05T14:08:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/annovis-bio-stock-reacts-to-webinar-plan-and-steep-discount-to-analyst-targets-60ea8056814b23fb 2026-09-05T14:02:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/european-healthcare-professionals-view-greener-pharmaceutical-manufacturing-favo-86972c80169790db 2026-09-05T12:58:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/synh-stock-reflects-syneos-health-s-move-to-go-private-bd6ccbf69dfad23d 2026-09-05T12:31:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/symbiosis-pharmaceutical-services-appoints-jos-vergeest-as-senior-business-devel-90c6b0f056e0860b 2026-09-05T12:29:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-ms-pill-that-beat-standard-therapy-and-cleared-the-safety-bar-its-rival-coul-59dc69ca9441f4d0 2026-09-05T12:23:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/before-the-first-molecule-making-better-target-and-modality-decisions-44248c637b5c8dfc 2026-09-05T11:59:06.000Z weekly 0.7 https://www.pharmaradar360.com/article/bpom-invites-pharmaceutical-industry-to-bolster-clinical-trials-3a5d10ffdcf5d92b 2026-09-05T11:47:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/personalized-cancer-vaccine-breakthrough-ignites-sequencing-sector-tempus-ai-s-p-d35b5a3721aae31d 2026-09-05T11:05:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-approves-first-drug-for-alexander-disease-247a4f900fe6e339 2026-09-05T10:47:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/crispr-therapeutics-gains-fda-approval-for-casg-2f0879fdfbacbdd9 2026-09-05T10:40:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/etfs-investing-in-beijing-sl-pharmaceutical-co-ltd-class-a-stocks-bbd678d351a029d1 2026-09-05T10:30:53.000Z weekly 0.7 https://www.pharmaradar360.com/article/nykredit-a-s-purchases-new-position-in-teva-pharmaceutical-industries-ltd-teva-49444cde7f7fa55b 2026-09-05T09:42:07.000Z weekly 0.7 https://www.pharmaradar360.com/article/adverum-biotech-advm-free-cash-flow-2024-92-8m-outflow-down-1-2-48a480bd60f45ef8 2026-09-05T09:09:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/medicines-discovery-catapult-backs-uk-biotech-innovators-b7fd54a7eaf805c9 2026-09-05T09:06:18.000Z weekly 0.7 https://www.pharmaradar360.com/article/two-scientists-made-huge-bets-on-impossible-cancer-treatments-they-re-finally-pa-db7a691a13ee6f25 2026-09-05T09:00:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-nyse-teva-given-average-rating-of-moderate-bu-2b9e2a547e63dda0 2026-09-05T08:33:53.000Z weekly 0.7 https://www.pharmaradar360.com/article/symbol-stock-quote-price-and-forecast-eb86857047c09609 2026-09-05T08:16:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/sls-stock-rises-overnight-healthcare-execs-tout-aml-drug-as-game-changer-ahead-o-12a417a1f58a5f3b 2026-09-05T07:59:33.000Z weekly 0.7 https://www.pharmaradar360.com/article/inhibrx-to-present-inbrx-106-phase-2-data-in-head-and-neck-cancer-study-7bc60e333f0cfecf 2026-09-05T07:31:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-extra-year-that-made-all-the-difference-2d795dc0f906e085 2026-09-05T07:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/tarsus-pharmaceuticals-acquires-alkeus-gildeuretinol-for-stargardt-disease-4dd965f22b50d017 2026-09-05T06:41:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/pelacarsen-fails-to-meet-primary-endpoint-in-phase-3-lp-a-trial-0ea1f443261d0062 2026-09-05T06:36:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/this-small-cap-biotech-posted-impressive-brain-cancer-data-but-there-s-a-catch-4e3e96481ca46f3d 2026-09-05T06:32:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/biomarin-pharmaceutical-bmrn-what-is-behind-the-fresh-attention-95db6bebddecf959 2026-09-05T05:39:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/astrazeneca-s-breast-cancer-drug-etcamah-gets-us-fda-approval-41925e83fc4b1cbb 2026-09-05T04:56:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/top-3-japanese-ai-healthcare-stocks-to-watch-in-september-2026-75b00280cb33900d 2026-09-05T04:40:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/hoth-s-pivot-from-biotech-to-space-tech-sparks-massive-rally-in-stock-retail-und-fea1a8d486dec34b 2026-09-05T04:33:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-grand-pharmaceutical-group-sehk-512-is-back-in-the-spotlight-12d7b62e79cc7d2b 2026-09-05T03:53:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/this-biotech-stock-crashed-28-today-after-announcing-second-reverse-share-split-b0b395313df17574 2026-09-05T03:29:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbv-stock-gains-on-winning-fda-approval-for-rare-blood-cancer-drug-1cabfd1aed67f747 2026-09-05T03:09:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-and-the-glp-1-story-behind-its-fair-value-gap-08239ff0c5b30182 2026-09-05T02:13:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-lp-a-drug-fails-to-lower-cardiovascular-risk-in-closely-watched-ph-3-tr-4ff0f635ef6e2a9a 2026-09-05T01:18:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-ultragenyx-pharmaceutical-rare-is-down-40-3-after-angelman-trial-failure-and-ec2e08344eda4d1e 2026-09-05T01:08:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32 2026-09-05T00:54:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-endoscopic-versus-shunt-treatment-of-hydrocephalus-in-infants-7bb9776f90b8cebc 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-mexican-teachers-cohort-study-genetics-and-cognitive-function-8748cd6c311b8bac 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-consortium-for-advancing-management-and-prevention-of-cancer-in-people-cfcd9f1e3695b9aa 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-aina-based-engagement-and-social-epigenomic-pathways-to-metabolic-heal-680bde3ce7adc92c 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-modeling-second-hit-somatic-mutations-in-hht-to-uncover-mechanisms-of-39b0d54321e66296 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-regulation-of-proteasome-activity-a44ed2c17835a78e 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-bacterial-survival-in-fluctuating-environments-stochastic-switches-rec-015dede062f415e7 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/elucidating-the-release-and-permeation-mechanisms-of-emulsion-type-cataplasms-fr-c42dc6128790d2ba 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-shelved-pipeline-ai-can-find-strategically-abandoned-medicines-and-bring-the-4f9bf51e7513fec4 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/persistence-of-immune-responses-5-years-after-vaccination-with-a-single-dose-of-e754be3d277811a2 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/efficacy-and-safety-of-dvdms-photodynamic-therapy-for-dysphagia-in-advanced-esop-f92c804ed3b86aec 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-analysis-of-antiviral-therapies-in-chronic-hcv-patients-clinical-out-4bcf8aa6f1254c3f 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comment-on-efficacy-and-safety-of-intraoperative-hyperthermic-intraperitoneal-ch-7f64a205b02b1996 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/alianza-terapeutica-y-cambio-clinico-en-psicoterapia-digital-una-revision-sistem-23f9bbee850cb5bf 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/seroprevalence-of-helicobacter-pylori-among-patients-attending-ignatius-ajuru-un-e817d25f76b3529f 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-profile-and-renal-anomalies-associated-with-culture-positive-urinary-tr-6a058814af559638 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-profile-and-outcomes-of-paediatric-traumatic-brain-injury-an-experience-b5e4628be31d8910 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-profile-and-outcome-of-childhood-cancer-over-2-years-at-a-tertiary-care-0901d6200d429697 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/lt-b-gt-acute-bacterial-meningitis-prevalence-clinical-profile-and-outcome-lt-b-44fb431196e05a86 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluation-of-the-three-component-drug-regimen-glutamyl-tryptophan-bendazole-asc-940b332fe1c13baf 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmacokinetic-parameters-of-a-combination-drug-containing-imidazolyl-ethylamid-0baeae1ef1811af1 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-chinese-medicine-compound-on-intestinal-bifidobacteria-recovery-and-cd-df2c56cc86dd2216 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/features-of-intestinal-lesions-in-the-clinical-course-of-inflammatory-bowel-dise-970e38ee5edd81b4 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/unusual-pulmonary-vein-variations-a-new-case-report-and-its-clinical-significanc-4bf10286dc5f4ada 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/impact-of-proton-pump-inhibitor-therapy-on-micronutrient-and-cognitive-function-62002486099678ba 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/phospholipid-drug-complex-tagged-snedds-lipid-based-approach-for-oral-bioavailab-c7c8e348c293d485 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-magnesium-supplementation-in-hypomagnesemia-on-wound-healing-in-diabet-3235a2566597306d 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/assessment-of-parent-s-knowledge-attitude-and-practice-regarding-self-medication-1a082b786f063c53 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-of-latent-fingerprints-using-air-dried-plant-extract-powders-an-eco-24b27d64d6b9e5da 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/serum-albumin-and-c-reactive-protein-as-predictors-of-intradialytic-hypotension-527e7083789e3728 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/indomethacin-loaded-nano-emulsions-a-promising-topical-platform-for-oral-mucosit-de142850bb89dfba 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effectiveness-of-a-structured-educational-intervention-on-internalized-shame-and-8a264b80d1242c1f 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-characteristics-and-risk-factors-for-trocar-site-hernia-a-single-center-6acba75f63e42b8d 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-effect-of-phase-i-cardiac-rehabilitation-exercise-training-combined-with-res-7e11f5cc1ac0f5aa 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/obstetric-and-non-obstetric-sources-of-maternal-sepsis-and-their-clinical-outcom-89a82e968531c98d 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/membrane-dependent-adsorption-of-lacosamide-in-crrt-implications-for-drug-dosing-11985cfa1e92275b 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/computational-mechanistic-analysis-of-olefin-formation-in-ketyl-radical-mediated-387a0d92a6b60c7c 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/vitamin-d3-attenuates-delirium-like-cognitive-impairment-in-a-postoperative-mous-eb241ee61b13fa6d 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sleep-disorders-and-type-2-diabetes-mellitus-a-narrative-review-of-evolving-rese-730f270c3499e5e1 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-nutrition-counseling-on-undernutrition-among-children-aged-6-23-months-663f1c3275a7ca69 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/beyond-the-clinic-a-feasibility-trial-of-the-super-skills-for-life-program-for-c-61c73a836a739fb4 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/breast-cancer-risk-epigenetic-aging-and-dna-methylation-clocks-dc075747faf8999c 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/occurrence-levels-of-alexithymia-in-clinical-nurses-a-systematic-review-and-meta-108c5446f3f8e4c7 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-context-feedback-visibility-cfv-framework-mechanisms-of-ai-empowered-clinica-7efd35f46f69cb99 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/critical-insights-into-metastatic-patterns-of-odontogenic-tumors-clinical-charac-eb9af3d399b9272e 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-consequences-treatment-status-and-parental-awareness-of-traumatic-denta-fc0a1196aaf37063 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/treatment-of-vulvovaginal-atrophy-using-vaginal-dilators-in-addition-to-usual-ca-4242fd54c94d016c 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/high-flow-nasal-cannula-versus-standard-oxygen-therapy-for-adult-acute-hypoxemic-d3e330c8f799849a 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/police-drug-seizures-without-arrest-before-and-during-a-decriminalization-pilot-688876b1023a3c02 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-and-validation-of-a-clinical-prediction-model-for-gastrointestinal-h-1b609f467ec5b699 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/zmynd11-mbtd1-rearranged-acute-myeloid-leukemia-in-chinese-adolescents-and-adult-d8038dd60bc332d8 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-characteristics-and-recovery-after-intravenous-thrombolysis-for-acute-i-1221e2272189e5a2 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-decision-making-and-management-of-gliomas-in-the-second-trimester-case-9fe4c99be97c0c3e 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/routine-clinical-test-markers-with-mri-anatomical-anchoring-for-dysphagia-risk-i-8d698514170983c8 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/blood-transcriptomic-profiling-identifies-hub-genes-with-diagnostic-and-clinical-3c85b97a8b7e0394 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/autonomic-regulation-as-a-mechanistic-pathway-linking-transcutaneous-auricular-v-8b6316e7240ed992 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/changing-clinical-presentation-of-pediatric-celiac-disease-over-time-632b1d895da2aaca 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/technology-meets-time-assessing-the-impact-of-clinical-decision-support-tools-fo-aae966df0229d21c 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/stroke-clinical-documentation-education-program-in-australia-and-new-zealand-c16e50de14a9a450 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/telehealth-in-pediatrics-a-quick-review-4397f75451a924a4 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/best-case-worst-case-a-multisite-randomized-trial-of-scenario-planning-for-patie-97c9bff1883fe3f8 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/financial-impact-of-a-long-acting-injectable-cabotegravir-rilpivirine-program-a-f2e44332314ebf3f 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-scandinavian-perspective-of-the-projected-lifetime-cost-effectiveness-of-rivar-f7f7bd844069977d 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ufasomal-nanocarriers-for-enhanced-cardiac-delivery-of-nifedipine-a-novel-strate-afda9338ec3346e3 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-of-hptlc-method-for-simultaneous-estimation-of-gatifloxacin-and-flur-3592b3a4c663329e 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/age-associations-sex-differences-and-interrelationships-of-five-skeletal-maturit-2bd54d31e65ec6bc 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gastrointestinal-tolerance-and-compliance-during-a-2-week-intervention-of-reform-a1263f1c370bc29d 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/investigating-the-short-term-reliability-of-health-related-physical-fitness-asse-5eeefa5eca21ad72 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/burden-of-complex-multimorbidity-and-disparities-in-care-and-support-among-older-657be33be128dfb8 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/artificial-intelligence-in-echocardiography-and-point-of-care-ultrasound-applica-d5c8cbce011330d7 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-of-a-recombinant-bacillus-ligniniphilus-l1-laccase-rice-straw-biocha-3b201a8978622e70 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/exploiting-binary-eutectic-fatty-acid-systems-for-thermoresponsive-nanocarriers-7f4d2fdc58ed3b61 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-efficacy-of-betamethasone-ciprofloxacin-and-saline-impregnated-nasal-a9a8c4422417da23 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/bulge-progenitor-cells-a-promising-frontier-in-hair-follicle-regeneration-and-cl-3d7c2672d8da15c8 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/antibody-drug-conjugates-in-the-treatment-of-esophageal-cancer-d07dfe0cb30e9961 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effects-of-supervised-exercise-immediately-after-bariatric-surgery-results-from-7145cbcebd22bb81 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cross-tier-implementation-gaps-in-pharmaceutical-waste-management-evidence-from-1b0cb6f2ef757071 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/institutional-phronesis-theorizing-how-us-primary-care-clinicians-navigate-compe-1dfeb77573914e75 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/systemic-evaluation-of-immune-cells-and-cytokines-in-patients-with-different-cli-30b411be4f72f0f0 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/concurrent-emergency-head-and-cervical-spine-ct-utilization-temporal-trends-diag-dc8d9f020852509c 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/moraxella-species-isolated-from-blood-cultures-in-europe-moraxeu-a-multicentre-s-9dbfe48cf40dc4fa 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ibero-american-consensus-on-reactive-arthritis-definition-diagnosis-and-manageme-059966e2abc9b36a 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/chloroquine-and-hydroxychloroquine-retinopathy-in-a-cohort-with-rheumatic-diseas-d7f29972f4ddb543 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-practice-guidelines-for-duodenal-cancer-2025-4164950c8ec243b7 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-effect-of-a-smartphone-based-educational-intervention-on-the-supportive-care-75ad4aa4690acbf1 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comment-on-survival-of-esophageal-squamous-cell-carcinoma-achieving-pathological-ed2136739cfc6e80 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-analysis-of-post-neurosurgical-intracranial-infections-distinct-clin-1129b9da52f1058f 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/video-assisted-versus-conventional-surgical-informed-consent-in-visceral-surgery-5313463edb15ecf5 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/when-88-meets-72-refining-the-clinical-relevance-of-cesarean-scar-disorder-crite-add3ff9d204cc156 2026-09-05T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-says-closely-watched-cholesterol-study-failed-to-meet-goal-c974947767e107ee 2026-09-04T23:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/retatutride-how-the-hunger-for-a-new-weight-loss-drug-is-feeding-an-industry-of-a21a403b35712d2a 2026-09-04T23:47:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/retatutride-how-the-hunger-for-a-new-weight-loss-drug-is-feeding-an-industry-of-3263ee450ff58f10 2026-09-04T23:47:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/krystal-biotech-president-r-d-suma-krishnan-sells-8-98m-in-stock-df91173fa47ede2e 2026-09-04T23:46:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/royalty-pharma-announces-update-on-novartis-phase-3-topline-results-for-pelacars-bc1f4aaad1074d58 2026-09-04T23:20:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/krystal-biotech-krys-r-d-head-sells-25-000-shares-under-trading-plan-cb1e83004cab11e9 2026-09-04T23:16:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/krystal-biotech-nasdaq-krys-ceo-sells-25-000-shares-under-trading-plan-769f72394190993e 2026-09-04T23:15:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-pharmaceutical-industries-limited-teva-discusses-positive-topline-results-f-1d262411b8d372e2 2026-09-04T23:08:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/why-microstructure-intelligence-matters-in-pharma-canva-4ef5ef0edcc9f338 2026-09-04T22:57:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmtech-weekly-roundup-september-4-2026-7533b9f88b60a135 2026-09-04T22:57:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/budget-for-specialty-pharmaceutical-benefits-set-at-6-73-billion-299e9cedc1dc9a28 2026-09-04T22:25:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/price-to-earnings-forward-of-beijing-science-sun-pharmaceutical-co-ltd-class-a-s-f590ad736661f465 2026-09-04T22:18:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/adrx-ipo-news-sirna-biotech-adarx-pharmaceuticals-files-for-a-100-million-ipo-30c48b5f6850499b 2026-09-04T22:06:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/health-care-down-on-retreat-from-risky-biotech-area-health-care-roundup-8a5b670f583adb85 2026-09-04T21:26:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmaceutical-temperature-controlled-shipping-boxes-market-outlook-to-2035-2902f61bf810da37 2026-09-04T21:21:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/louisiana-et-al-v-food-and-drug-administration-a-case-working-its-way-through-fe-66ad1de31182382d 2026-09-04T21:16:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-experimental-cardiovascular-drug-fails-a-pivotal-study-9ae30b6c2563ebf7 2026-09-04T21:13:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/matinas-biopharma-receives-notice-of-non-compliance-with-nyse-american-continued-a3f827cc018f20b4 2026-09-04T21:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-rallies-hrt-manufacturers-amid-us-wide-estradiol-patch-shortage-efd1ca9295aa5ff4 2026-09-04T20:37:36.000Z weekly 0.7 https://www.pharmaradar360.com/article/krystal-biotech-nasdaq-krys-holder-to-sell-25-000-founders-shares-7f15233a6b29e374 2026-09-04T20:35:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/krystal-biotech-krys-insider-moves-to-sell-2017-shares-in-a-multimillion-dollar-ca5b3b0ebae69cca 2026-09-04T20:34:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-announces-lp-a-horizon-phase-iii-topline-results-for-pelacarsen-in-pati-867479c87b906007 2026-09-04T20:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/anmat-emitio-una-carta-de-advertencia-a-ugal-farmaceutica-s-a-por-incumplimiento-3ee3a16bbcc2f661 2026-09-04T20:25:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-clears-ind-for-acepodia-s-dual-payload-adc-ace723-562cd23a52fb1859 2026-09-04T19:55:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-virtus-lifesci-biotech-products-etf-bbp-affects-rotational-strategy-timing-ba10d3e23ea6d928 2026-09-04T19:54:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/price-to-sales-forward-of-ch-biotech-r-d-co-ltd-twse-6534-c184512b86e2c429 2026-09-04T19:31:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/vertex-vs-regeneron-which-biotech-giant-is-the-better-buy-right-now-d7df5d6599582fab 2026-09-04T19:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cipla-partners-with-qilu-pharmaceutical-to-commercialize-a-keytruda-biosimilar-i-02acbe0f0bb78c07 2026-09-04T19:27:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/gan-lee-pharmaceuticals-ade7c29f5fb27ce0 2026-09-04T19:22:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-green-light-for-zanvastro-in-alexander-disease-f88683f75405f5fc 2026-09-04T19:04:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/anmat-presento-la-experiencia-argentina-en-vigilancia-y-control-post-comercializ-2488a1f0ffb5901f 2026-09-04T19:04:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/vertex-vs-regeneron-which-biotech-giant-is-the-better-buy-right-now-793b08ac95d107c2 2026-09-04T19:03:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/vertex-vs-regeneron-which-biotech-giant-is-the-better-buy-right-now-f1e282e1506ed3dc 2026-09-04T18:50:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-pharmaceutical-industries-nyse-teva-price-target-raised-to-48-00-at-ubs-gro-3718e94073907b30 2026-09-04T18:45:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/beone-onc-secured-a-pharmaceutical-tariff-exemption-after-more-than-1b-of-u-s-ma-75b7a23003457f36 2026-09-04T18:44:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/porcine-kidney-xenotransplantation-as-a-bridge-to-allotransplantation-a-first-in-5c486e8a729f25d2 2026-09-04T18:16:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-goldman-sachs-group-issues-pessimistic-forecast-for-ultragenyx-pharmaceutica-679089eff3672c38 2026-09-04T18:15:39.000Z weekly 0.7 https://www.pharmaradar360.com/article/jos-vergeest-appointed-at-symbiosis-bringing-three-decades-of-pharmaceutical-exp-5f4fcc7a587f046f 2026-09-04T18:06:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/rare-brain-disorder-gets-its-first-fda-drug-approval-c9ccac9f39aac17f 2026-09-04T17:52:34.000Z weekly 0.7 https://www.pharmaradar360.com/article/how-pharma-will-navigate-the-ndc-12-transition-1f1847cc4d566e17 2026-09-04T17:51:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-pauses-autoimmune-car-t-trials-following-three-deaths-a0de109acce01059 2026-09-04T17:46:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/h-c-wainwright-maintains-legend-biotech-legn-us-with-buy-rating-maintains-target-6ca84d6d182f68e0 2026-09-04T17:42:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/police-response-insufficient-for-crimes-against-pharmacies-report-owners-d78a9e8392e46ad6 2026-09-04T17:38:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/call-to-expand-shingles-vaccine-following-cardiovascular-research-bf9e54f857af915a 2026-09-04T17:38:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-approves-zanvastro-pharmexec-ae001a6459d6b4f4 2026-09-04T17:37:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/maharashtra-fda-strikes-again-closes-canteen-at-thane-government-hospital-after-d572cd8cb0d16e22 2026-09-04T17:33:35.000Z weekly 0.7 https://www.pharmaradar360.com/article/medicines-discovery-catapult-backs-two-u-k-biotech-companies-tackling-chronic-di-2a91e1113b88c4ae 2026-09-04T17:28:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/news-biotech-firm-inks-office-deal-in-south-san-francisco-cb565b9f4316a748 2026-09-04T16:55:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/cockroach-found-in-patient-s-meal-fda-flags-violations-shuts-thane-hospital-cant-ac237dad9aeb2eb7 2026-09-04T16:38:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/novo-nordisk-advances-new-injectable-obesity-drug-in-key-phase-3-trial-55906840ab9c4121 2026-09-04T16:34:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/pfizer-s-tilrekimig-eczema-trial-a-fresh-phase-3-catalyst-for-pfe-investors-e00d8772d820793f 2026-09-04T16:34:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/medtronic-executives-to-speak-at-upcoming-investor-conferences-fe0d7b9078a66a84 2026-09-04T16:34:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/this-biotech-wins-a-big-fda-approval-why-wall-street-is-shrugging-12974b5b8bd07770 2026-09-04T16:13:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/trailing-rivals-abbvie-scores-win-with-dual-acting-myeloma-drug-43b029fb663ef74c 2026-09-04T16:10:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/registration-open-for-sacramento-biotech-summit-at-aggie-square-9524742bf36c6654 2026-09-04T16:05:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/genencell-s-book-value-hits-zero-amid-allegations-kim-seung-won-sought-clinical-5a6dd76f4aaac2ed 2026-09-04T16:05:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ai-is-revolutionizing-biotech-can-regulation-keep-up-adcb553923ba9ce2 2026-09-04T15:57:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-stocks-to-watch-and-pharma-industry-news-72f24107382921a8 2026-09-04T15:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharma-pulse-mfn-expansion-goodrx-s-family-plan-csafe-s-reusable-cover-bb893e9003f89293 2026-09-04T15:44:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-upgraded-to-investment-grade-by-s-p-global-ra-5a9fbf7fc25733d9 2026-09-04T15:40:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-wall-street-analyst-spotted-the-trial-freeze-then-came-news-of-three-deaths-25accbeac58f1638 2026-09-04T15:33:19.000Z weekly 0.7 https://www.pharmaradar360.com/article/daiichi-unit-american-regent-recalls-3-epinephrine-batches-on-particulate-leakag-9cab5fe17071222c 2026-09-04T15:12:25.000Z weekly 0.7 https://www.pharmaradar360.com/article/va-secures-10b-in-pharmaceutical-price-reductions-so-far-in-fy-2026-e5596cc90a2b64ca 2026-09-04T15:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/russia-attacks-teva-pharmaceutical-company-and-world-health-organization-warehou-01cc1de6ad42dde7 2026-09-04T14:51:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/former-i-mab-chief-joan-shen-s-neushen-banks-80m-for-3-brain-health-drugs-ac240652b9285082 2026-09-04T14:47:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/veraxa-biotech-stock-rises-after-naming-raju-willener-as-cfo-by-investing-com-7a40239d54805b10 2026-09-04T14:43:53.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-digest-expedited-regulatory-pathways-for-biologics-79b10a02d16847cd 2026-09-04T14:43:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/cipla-announces-exclusive-partnership-with-qilu-pharmaceutical-for-the-licensing-b2c729fc50676a80 2026-09-04T14:24:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-indonesia-to-the-world-support-beta-pharmacon-s-manufacturing-excellence-wi-c162257ad511f15b 2026-09-04T14:22:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-is-back-with-h1-progress-smoothing-glide-path-through-end-of-year-truist-2ed583a9b16ec59c 2026-09-04T14:11:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/weekly-buzz-ions-mist-biib-azn-win-nods-tcrx-nvs-cut-jobs-ovid-vir-data-regn-pas-e786e36eef9e1887 2026-09-04T14:09:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/federal-appeals-court-to-consider-louisiana-s-arguments-for-banning-telehealth-a-176f77491e2393f9 2026-09-04T14:04:53.000Z weekly 0.7 https://www.pharmaradar360.com/article/q-a-mckesson-s-scott-mooney-on-closing-dscsa-data-exchange-gaps-6c5b4921e97cadab 2026-09-04T14:04:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/cover-of-vaccination-evaluated-rapidly-cover-programme-april-2025-to-march-2026-bf86900b8a68bc94 2026-09-04T14:00:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-takes-another-look-at-botanical-drugs-5d3fbf966f8a0faf 2026-09-04T13:51:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/cockroach-found-in-patients-meal-fda-shuts-down-kalwa-hospital-canteen-after-ins-a1552b2176401afc 2026-09-04T13:49:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/top-biotech-deals-in-august-2026-648c8cfdb1b56b15 2026-09-04T13:21:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/barclays-issues-pessimistic-forecast-for-ultragenyx-pharmaceutical-nasdaq-rare-s-941455bfd6b4c414 2026-09-04T13:16:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/israeli-biotech-firm-picks-indiana-for-north-american-headquarters-00dcd5724fbe51b3 2026-09-04T13:04:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/clearmind-medicine-stock-slides-friday-what-s-happening-e87647c65615b7b7 2026-09-04T12:59:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/huntsville-biotech-company-diatherix-laboratories-to-close-55-jobs-affected-14e605b10dab7b04 2026-09-04T12:52:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-potentially-blinding-eye-disease-has-no-fda-approved-therapy-tarsus-bought-a-c-05f52a650d30f2e8 2026-09-04T12:42:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/jeol-launches-benchtop-scanning-electron-microscope-fe29c93ef626d8e3 2026-09-04T12:37:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-year-after-big-pharma-s-pull-back-from-the-uk-what-s-changed-91ea46f4b66d8ec6 2026-09-04T12:36:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-s-etentamig-cuts-risk-of-progression-by-60-in-phase-3-multiple-myeloma-tr-005918f5e5ae6fbb 2026-09-04T12:31:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/thyroid-medication-lot-recalled-nationwide-98aeb5228b273e29 2026-09-04T12:28:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/roche-gets-phase-3-trial-waiver-for-higher-dose-of-multiple-sclerosis-drug-c9bae14d474c5b7a 2026-09-04T12:26:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/251b583e1d4ec3f7 2026-09-04T12:15:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/lifepak-35-monitor-defibrillator-6c5b82584c6ee1da 2026-09-04T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/imagertm-ii-angiographic-catheter-31ad1b2e722a9f05 2026-09-04T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gore-viabahn-endoprosthesis-with-propaten-bioactive-08e5d69ab1e55cb9 2026-09-04T12:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/vrxa-424b-filings-veraxa-biotech-ag-sec-424b-127f1370dd1cec28 2026-09-04T11:51:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/finance-veteran-behind-chf-30b-portfolios-joins-veraxa-biotech-vrxa-as-cfo-87a630a710fcafa4 2026-09-04T11:46:49.000Z weekly 0.7 https://www.pharmaradar360.com/article/veraxa-biotech-names-raju-willener-as-chief-financial-officer-2ada056d45deccc0 2026-09-04T11:36:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/h-c-wainwright-reiterates-legend-biotech-stock-rating-at-buy-3cf72a995f724227 2026-09-04T11:32:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/dimerix-secures-a-34-million-non-dilutive-facility-to-fund-key-clinical-mileston-11179059e4b6422a 2026-09-04T11:27:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/acepodia-announces-fda-clearance-of-ind-application-for-ace723-a-novel-dual-payl-ae666f0288e1ecfe 2026-09-04T11:27:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/from-drug-substance-to-drug-product-why-integration-matters-in-modern-pharmaceut-6b10776e1e0e3d1e 2026-09-04T11:24:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/lipofit-extreme-fat-burner-recall-fda-finds-toxic-dnp-and-hidden-drug-f7a329c1cd0a7de3 2026-09-04T11:17:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/govt-launches-bio-nivesh-to-drive-private-capital-into-biotech-startups-5267194874c2709e 2026-09-04T11:15:57.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-pipac-pilot-validating-api-platform-3f397b3ff13ce3bd 2026-09-04T11:12:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/eli-lilly-pharmaceutical-plant-in-upper-macungie-takes-another-step-forward-95d1e0cf0664292e 2026-09-04T11:10:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-nasdaq-rare-rating-lowered-to-hold-at-royal-bank-of-ca-97ea518a6d4e3d57 2026-09-04T11:09:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-intensifies-food-safety-checks-across-goa-cb100a065a1e2f6c 2026-09-04T11:09:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/huntsville-biotech-company-to-close-laying-off-55-workers-be095482a50e2d74 2026-09-04T11:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-organoid-technologies-for-disease-modeling-drug-discovery-and-dev-ee280dd7c9dfc991 2026-09-04T10:44:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-european-rare-diseases-research-alliance-53102f99bfd75eb8 2026-09-04T10:44:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-understanding-frailty-towards-a-future-of-healthy-ageing-9a110880d5f55f8c 2026-09-04T10:44:27.000Z weekly 0.7 https://www.pharmaradar360.com/article/cordis-project-next-generation-x-ray-laser-light-sources-aeb2e2dfc2e128c8 2026-09-04T10:44:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/bright-minds-biosciences-stock-slides-4-82-as-biotech-volatility-bites-is-more-d-5d0ded2b47af50c1 2026-09-04T10:38:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/perkinelmer-acquires-simotech-to-expand-pharma-manufacturing-automation-25f366eb27ff01e4 2026-09-04T10:36:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/ubs-raises-teva-pharmaceutical-stock-price-target-on-celiac-progress-2a1cb027796bdb4d 2026-09-04T10:36:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ionis-nets-zanvastro-us-approval-in-first-for-alexander-disease-24d83c4ae6c3e865 2026-09-04T10:34:44.000Z weekly 0.7 https://www.pharmaradar360.com/article/trials-by-design-inside-the-new-good-clinical-practice-guideline-6ced499fbb622cde 2026-09-04T10:31:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-nitrosamine-saga-how-one-impurity-rewrote-global-quality-rules-68994d10af08aad4 2026-09-04T10:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/corporate-report-mhra-nice-real-world-evidence-scientific-dialogue-c822a3e3b6d68c78 2026-09-04T10:18:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/la-aemps-informa-de-un-fallo-en-determinados-respiradores-newport-ht70-plus-y-pi-82e0e3d07eaa76ab 2026-09-04T10:11:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/partnership-to-identify-novel-drug-targets-in-neurological-diseases-f341779c9a2a5b0b 2026-09-04T10:10:51.000Z weekly 0.7 https://www.pharmaradar360.com/article/kylo-11-s-97-lp-a-reduction-from-a-single-dose-rewrites-the-durability-standard-d4a5341776eda0a2 2026-09-04T10:07:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/your-questions-answered-the-biggest-pharma-and-biotech-stories-this-week-2a623b8652ef2c75 2026-09-04T10:07:52.000Z weekly 0.7 https://www.pharmaradar360.com/article/superluminal-raises-60-million-to-take-obesity-drug-into-clinic-c7b6cd6243bba671 2026-09-04T09:50:24.000Z weekly 0.7 https://www.pharmaradar360.com/article/decision-human-and-veterinary-medicines-register-of-licensed-manufacturing-sites-de9ea64f4d4c5e91 2026-09-04T09:38:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/notice-register-of-brokers-authorised-to-deal-in-human-medicines-591cf296afe9cc7a 2026-09-04T09:38:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/decision-medicines-new-manufacturing-and-wholesale-dealer-licences-f73993bdb326b18f 2026-09-04T09:38:17.000Z weekly 0.7 https://www.pharmaradar360.com/article/notice-medicines-terminated-and-cancelled-manufacturing-and-wholesale-dealer-lic-85a664947262b9cb 2026-09-04T09:38:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/decision-human-medicines-register-of-licensed-wholesale-distribution-sites-6901963b073e5f1a 2026-09-04T09:38:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/cee-startup-tech-weekly-new-capital-flows-into-ai-biotech-medtech-and-more-d5cb89512c95cd85 2026-09-04T09:33:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/nsf-launches-three-new-science-and-technology-centres-2965520de44b468f 2026-09-04T09:23:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-stocks-at-52-week-highs-atto-halo-ikt-tvtx-atrc-38a6ce892e6ee1f3 2026-09-04T09:15:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/rakovina-therapeutics-shifts-72-of-budget-to-ai-cancer-programs-4fe1118ec6da23ab 2026-09-04T09:11:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/myamici-and-my-green-lab-collaborate-to-improve-sustainable-lab-purchasing-4d8e208884ea3e93 2026-09-04T09:05:29.000Z weekly 0.7 https://www.pharmaradar360.com/article/takeda-pharmaceutical-tse-4502-wins-mimrylo-approval-is-the-stock-still-trading-faa2c56c2669f565 2026-09-04T09:02:48.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-sensors-behind-pharmaceutical-monitoring-6be7cd5b8bc3f6cc 2026-09-04T08:53:10.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-discovery-alone-does-not-change-a-life-biotech-executive-says-eabe16cd0617d45a 2026-09-04T08:52:16.000Z weekly 0.7 https://www.pharmaradar360.com/article/wellington-management-group-llp-reduces-stock-position-in-ultragenyx-pharmaceuti-8c69afe9c0111bad 2026-09-04T08:45:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-approves-first-ever-drug-for-alexander-disease-e097dbb9bd0de18e 2026-09-04T08:44:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/russia-has-attacked-a-teva-pharmaceutical-company-warehouse-in-ukraine-twice-da4d0af29b8c3bc4 2026-09-04T08:34:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/measles-epidemiology-2023-to-2026-1387e9c40489bd37 2026-09-04T08:30:02.000Z weekly 0.7 https://www.pharmaradar360.com/article/melbourne-biotech-immunobiota-progresses-5m-seed-raise-for-world-first-oral-type-b4d5cb9476bd3fbd 2026-09-04T08:27:21.000Z weekly 0.7 https://www.pharmaradar360.com/article/medytox-expands-damages-claim-against-daewoong-pharmaceutical-tenfold-to-500-bil-2f736c6111e11e23 2026-09-04T08:25:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/boletin-sobre-seguridad-de-medicamentos-de-uso-humano-julio-de-2026-c127410c2324efee 2026-09-04T08:19:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/jw-pharmaceutical-launches-chewable-eye-nutrition-candy-eye-crunch-60f809e8ab7fce04 2026-09-04T08:06:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/teva-ukraine-warehouse-hit-twice-in-russian-attack-raising-supply-concerns-f938679799fa6ad7 2026-09-04T07:47:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/argo-s-bw-20805-achieves-96-attack-rate-reduction-in-hae-phase-ii-342c8364b7f69850 2026-09-04T06:40:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/ivonescimab-beats-pembrolizumab-on-overall-survival-in-phase-3-nsclc-trial-26a34a5b8cbfe31c 2026-09-04T06:35:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/hanchorbio-submits-ind-to-u-s-fda-for-hcb303-its-second-tri-specific-immunothera-5b8896c62efe16f0 2026-09-04T06:26:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-advisory-no-2026-1020-public-health-warning-against-the-purchase-and-use-of-a6df66299070d3dc 2026-09-04T06:03:14.000Z weekly 0.7 https://www.pharmaradar360.com/article/accelerated-amortized-payment-of-convertible-bond-installment-e9e80f19df8ee3e8 2026-09-04T06:02:05.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-advisory-no-2026-1019-public-health-warning-against-the-purchase-and-use-of-d48cd80405cdd564 2026-09-04T05:58:13.000Z weekly 0.7 https://www.pharmaradar360.com/article/sanofi-stock-holds-steady-as-pipeline-data-keeps-focus-on-long-term-239bfcdc011eb9f0 2026-09-04T05:49:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/number-of-shareholders-of-aurisco-pharmaceutical-co-ltd-class-a-sse-605116-06b066c3fb923415 2026-09-04T05:45:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/hanmi-s-once-weekly-hyperinsulinism-drug-advances-in-global-phase-2-321cbe0887abe385 2026-09-04T05:26:50.000Z weekly 0.7 https://www.pharmaradar360.com/article/kangmei-pharmaceutical-banks-on-centralized-procurement-for-expansion-upgrading-694812ab8349f82c 2026-09-04T05:07:20.000Z weekly 0.7 https://www.pharmaradar360.com/article/capital-raising-in-healthtech-singular-photonics-aisel-health-and-trinity-biotec-05ca86013071b2fa 2026-09-04T05:05:11.000Z weekly 0.7 https://www.pharmaradar360.com/article/drugs-and-biologics-5th-cir-fifth-circuit-upholds-fda-s-removal-of-tirzepatide-f-3cd04fea308b8823 2026-09-04T05:01:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/gsk-bets-nearly-1-3-billion-on-hutchmed-s-attc-platform-as-chinese-innovative-dr-2dedf8f6544a45ac 2026-09-04T04:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hanmi-pharmaceutical-completes-phase-2-dosing-of-rare-disease-drug-ea619ac6bd578fa6 2026-09-04T04:50:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/suven-life-sciences-completes-phase-3-enrollment-for-masupirdine-in-alzheimer-s-2900b13463d2bb5e 2026-09-04T04:47:23.000Z weekly 0.7 https://www.pharmaradar360.com/article/party-drug-mdma-approved-by-new-zealand-to-treat-trauma-8d151b223f52b56b 2026-09-04T04:36:45.000Z weekly 0.7 https://www.pharmaradar360.com/article/gc-biopharma-pushes-into-senior-flu-vaccine-market-with-phase-2-3-trial-1d81c1eda1185c5c 2026-09-04T04:26:03.000Z weekly 0.7 https://www.pharmaradar360.com/article/abbvie-named-official-pharmaceutical-sponsor-of-pga-tour-and-2026-presidents-cup-38bec09ca54775a9 2026-09-04T04:07:30.000Z weekly 0.7 https://www.pharmaradar360.com/article/pharmexcil-to-host-trade-expo-next-week-eyes-1-4-bn-export-opportunities-63091a9298bc8d25 2026-09-04T04:05:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/women-in-clinical-trials-history-and-impact-4e9a42d030d09131 2026-09-04T04:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/40kg-expired-chilli-mixed-meat-and-veg-bengaluru-s-chairman-s-club-kitchen-shut-2e3c3c4c0c15fb56 2026-09-04T03:40:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sen-warren-demands-answers-from-rfk-jr-over-calamitous-response-to-cyclosporiasi-597f451e02e55a45 2026-09-04T03:10:43.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-on-alert-maharashtra-food-safety-body-rolls-out-hit-list-for-upcoming-festiv-ee15b7cb545e9138 2026-09-04T03:00:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/dimerix-secures-a-34-million-non-dilutive-facility-to-fund-key-clinical-mileston-6092f19054abd1ee 2026-09-04T03:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/genscript-biotech-proposes-spin-off-separate-listing-of-probio-unit-5d18af77e433e3d1 2026-09-04T02:53:28.000Z weekly 0.7 https://www.pharmaradar360.com/article/hutchmed-signs-licensing-deal-with-gsk-for-experimental-solid-tumour-drug-89fa778161cb6ca2 2026-09-04T02:47:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-approves-first-ras-targeting-drug-for-pancreatic-cancer-4302da7134eee7fd 2026-09-04T02:25:01.000Z weekly 0.7 https://www.pharmaradar360.com/article/sino-biopharmaceutical-s-gpc3-adc-drug-wins-fda-clinical-trial-approval-shares-s-dd1df1155335a767 2026-09-04T01:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-rare-reports-61-cornstarch-reduction-in-96-week-phase-a8232257af147e0f 2026-09-04T01:38:09.000Z weekly 0.7 https://www.pharmaradar360.com/article/us-president-trump-posts-on-truth-social-a-request-from-senator-grassley-for-tru-483ddba2b495b9a6 2026-09-04T01:27:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/dimerix-secures-non-dilutive-funding-for-key-kidney-disease-programs-9f824b90f99b62c1 2026-09-04T00:29:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cipla-licenses-china-s-qilu-pharmaceutical-keytruda-biosimilar-us-rights-ed32477bbc498067 2026-09-04T00:02:08.000Z weekly 0.7 https://www.pharmaradar360.com/article/gc-biopharma-wins-korea-approval-to-run-phase-2-3-trials-of-high-strength-flu-sh-aade03aacbdc6c08 2026-09-04T00:01:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/novartis-filed-form-6-k-7fe35a5b8dd5ee97 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/reducing-bureaucracy-and-burden-for-the-repatriation-of-mentally-ill-nationals-b7a59fc750d4cf35 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/advancing-development-of-botanical-drug-products-request-for-information-54023367d77f8ebc 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/performance-review-board-members-3d2655a4c40f3ce0 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agency-information-collection-activities-submission-to-omb-for-review-and-approv-26d2dab5b5978447 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-perceived-norms-about-alcohol-use-and-hiv-sti-prevention-among-adolesc-4a90d5787098a896 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-the-adhincra-study-addressing-hypertension-care-in-africa-f1880d4aca92881e 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-inborn-errors-of-immunity-underlying-herpes-simplex-encephalitis-11d45dc8a77cd184 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-single-session-intervention-and-interpersonal-therapy-for-adolescent-d-fd8666ae37c21612 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-brain-injury-and-dysmaturation-in-newborns-with-congenital-heart-disea-39627100803f5414 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-development-of-protein-mri-contrast-agent-for-precision-imaging-lung-f-08ecf70a0837c64e 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-regulation-and-role-of-pdc-in-immunopathogenesis-of-hbv-hiv-co-infecti-026e9da61fe27a04 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-mapping-the-development-of-episodic-memory-b7e59b6dcf3b5b45 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-genetic-etiologies-of-subclassifiable-ild-study-the-genesis-cohort-stu-392f5e6dc7e3a200 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-career-enhancement-core-702e6d4d6b48801b 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-pilot-feasibility-core-8ef4149e6518dfe3 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-circuit-logic-and-functional-dissection-of-the-intrinsic-cardiac-nervo-03965b5a14dd6866 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-investigating-the-function-of-aberrant-rna-in-cancer-992f235d243cb07f 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-health-trajectories-during-transitions-into-and-out-of-caregiving-in-l-1373a1f6afc5c1af 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-training-in-the-design-and-development-of-infectious-disease-therapeut-69320fb38c857875 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-digital-biomarker-discovery-with-multimodal-and-longitudinal-wearable-d108ab68ab5915bf 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-phenix-providing-high-quality-software-to-the-research-community-for-c-f84e066bc0f3a9ce 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-career-enhancement-program-e1a6233ff3d39c27 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-project-2-mechanisms-of-resistance-to-neoantigen-vaccines-in-pdac-2babd0476a227c11 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-mechanistic-and-translational-medicine-studies-of-brain-neurophysiolog-26444182a54d8aa9 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-fast-dissolving-mm008-tablet-for-instant-on-demand-non-hormonal-contra-fd5595059acf3241 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-developing-a-cancer-galaxy-computational-workbench-to-meet-emerging-ca-dd2a647b3a0a3088 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-synergistic-epidemics-of-non-communicable-diseases-stigma-depression-a-2ae382487b70b360 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-blood-based-neurodegenerative-disease-biomarkers-environment-and-demen-07f96d4e9d9d0691 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-the-contribution-of-the-mammalian-visual-cortex-to-stabilizing-locomot-08ad67efcdace1a9 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-icreate-increasing-capacity-for-injury-research-in-eastern-europe-0f4463f83fd16016 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-scholars-in-oncology-associated-research-soar-78bfa3a7f15b7b9c 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-head-and-neck-cancer-spore-1b353ef8931fa9ff 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-ny-screenplus-a-comprehensive-flexible-multi-disorder-newborn-screenin-c7a75d3127cf9192 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-risk-factors-for-end-stage-glenohumeral-osteoarthritis-c806c789d3707270 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-multiscale-simulations-of-biological-systems-and-processes-2bcf9e696985e063 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-neurobiological-mechanisms-of-fatigue-in-health-and-after-covid-19-634b0196a37c0929 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-inner-ear-infection-and-innate-immunity-2bea6c71da08275e 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-e3-ubiquitin-ligase-chfr-regulates-lung-endothelial-barrier-integrity-f2ce999a4e41a7b5 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-a-novel-method-of-non-invasive-brain-stimulation-to-enhance-motor-func-2f313f904e0e4bef 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-targeting-cancer-at-the-protein-membrane-interface-6032b5fcee6abdc6 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-ancestry-and-sex-related-pharmacogenomic-and-metabolomic-signatures-of-eb59b487d83dbe15 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-fda-phase-1-development-of-a-novel-nonopioid-cell-and-tissue-permeable-8ca9612f063c4ba6 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-i-institutional-career-development-core-b78cb31851c806a0 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-boosting-treatment-effects-on-teenage-binge-drinking-with-a-mechanisti-2b6e01113590389b 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-leveraging-a-card-study-methodology-to-promote-integration-of-genetics-b36ab3b7430423d2 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-subclinical-kidney-and-cardiovascular-indicators-of-transplant-associa-63831f5867eb3a77 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-optimizing-modiflow-geometry-for-enhanced-efficiency-of-aerosol-drug-d-0482f6e3278f60e4 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-combating-aps-associated-neutrophil-activation-with-colchicine-616040fa692ebcc3 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-identifying-unmet-needs-to-support-individuals-impacted-by-misattribut-e14df49f0402bb05 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-engineering-neuroresilience-investigating-tardigrade-neuroprotection-t-4a2f5ccd9b6898dc 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-development-and-validation-of-a-cell-separation-platform-technology-a73c3c5f21ca2644 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-understanding-gastrointestinal-cancer-disparities-among-native-hawaiia-8d3a88cdba97e608 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-core-2-advanced-dosimetry-modeling-biostatistics-d4d9637e32fc0b0c 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-core-1-biorepository-data-acquisition-c8b6fd1b7eae6ac8 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-project-3-plasma-and-tissue-biomarkers-in-neoadjuvant-crt-for-egc-f2fec1e3ea8e4312 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-a-randomized-trial-to-determine-impact-cost-and-cost-effectiveness-of-a1c9695b0d1dd1ed 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nih-award-measuring-input-output-operations-of-cortical-neurons-with-large-scale-c10e6d45c8b79ddf 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/tips-for-coping-with-end-of-summer-blues-35de06e0b57dfafe 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/relationship-between-factors-of-mental-and-physical-health-in-medical-students-5f4b30f8c5cebbd6 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/personme-a-clinical-trial-for-personalised-psychiatry-from-your-sofa-fdb0d02e2653888e 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-women-centred-approach-development-of-a-randomized-controlled-trial-evaluating-164df61e7f370587 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/randomized-clinical-trial-of-a-novel-food-insecurity-intervention-for-patients-w-5dafe13c8fbb030e 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/switching-from-amisulpride-to-cariprazine-real-world-outcomes-in-patients-with-p-6f6571b1e0beb808 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/an-open-label-trial-to-compare-exposures-of-subcutaneous-long-acting-injectable-8c3b310a36dec4f3 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/agreement-and-divergence-between-clinician-rated-and-self-report-measures-of-dep-70097379c2737666 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/demographic-disparities-in-clinical-trials-of-xanomeline-trospium-for-schizophre-428f2e0cef81b3e7 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/industry-updates-from-the-field-of-stem-cell-research-and-regenerative-medicine-6b48f3f63dfb8db3 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/esketamine-for-postoperative-anxiety-after-major-abdominal-tumor-surgery-a-rando-0c34b286b8bdc78f 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/letter-to-the-editor-regarding-effects-of-desflurane-and-propofol-general-anesth-0a62643203b11b68 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/discovering-repurposable-drugs-for-alzheimer-s-disease-and-related-dementias-tar-c708395ca028783f 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-landscape-analysis-of-japanese-tolerability-assessments-in-oncology-drug-devel-c3535d8f78f44868 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/characterizing-time-toxicity-in-lung-cancer-clinical-trials-development-and-appl-a2870b4a04cdc3df 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/safety-and-pharmacokinetics-of-cl-197-a-potent-compound-with-low-cytotoxicity-ag-ced65a36a1609c65 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/long-term-hormone-therapy-for-perimenopausal-and-postmenopausal-women-57a9a2c991633765 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/a-review-of-seamless-phase-i-ii-trial-designs-towards-oncology-dose-optimization-fc2481260a3cef12 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/antimicrobial-susceptibility-patterns-among-urinary-bacterial-isolates-a-descrip-ef8277884994cecd 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-and-immunological-characteristics-of-atopic-dermatitis-severity-in-chil-aa888a38d7392ed8 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/computed-tomography-portal-venous-reconstruction-assisted-endoscopic-ultrasound-764a4336448750ea 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparative-in-vitro-evaluation-of-systemic-fungicides-and-bioagents-against-pig-eb3ba59e33cd559f 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/lt-b-gt-prevalence-clinical-profile-and-risk-factors-of-peripheral-arterial-dise-b265cf5191c80bd0 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-complexities-in-vulnerable-populations-a-comprehensive-review-of-hemoph-9aed9920ff9c7dc3 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-clinical-spectrum-of-adult-patients-with-hypercalcaemia-attending-a-tertiary-26b79d9d01868107 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/changing-clinical-characteristics-diagnostic-patterns-and-outcomes-of-tuberculos-8c36d12855f22fad 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-outcomes-of-radiation-therapy-as-an-alternative-to-radical-surgery-for-4136b3aadd36e529 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cyp2d6-genetic-variation-and-clinical-response-to-donepezil-and-galantamine-in-a-dae04cbba6871929 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/inflammatory-bowel-disease-in-kazakhstan-phenotypes-disease-activity-and-treatme-be2cf4c817d987d4 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/real-world-treatment-patterns-and-clinical-outcomes-after-first-line-therapy-in-dd7ac1900ddf7276 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effects-of-21-day-vitamin-d-supplementation-on-sports-performance-and-exercise-i-f6005a17065d504f 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/autogluon-based-interpretable-machine-learning-for-clinical-risk-stratification-81eb8b46cadb4655 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/anastomotic-leak-after-esophagectomy-for-cancer-in-enhanced-recovery-protocol-ve-f978ea451f1a066e 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/an-open-label-randomised-controlled-trial-protocol-evaluating-a-siddha-add-on-re-70da0d96993a362f 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/short-term-postoperative-neurocognitive-safety-and-recovery-profiles-of-remimazo-7581cfb050d0396e 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/synergistic-effect-of-insulin-resistance-and-glycemic-variability-on-mortality-i-14988ea6116385ab 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/spatial-niches-of-the-colorectal-cancer-microbiome-differences-interrelationship-9d0da07599e2a98e 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/spontaneous-coronary-artery-dissection-in-sweden-epidemiology-diagnostics-and-cl-7d279917dfad0941 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/current-review-of-pediatric-fas-associated-death-domain-protein-deficiency-expan-5974ea24c31e9923 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-feasibility-and-image-quality-assessment-of-deep-learning-based-virtual-431565aded3c343a 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-coated-balloons-from-evidence-to-practice-and-a-proposed-antithrombotic-the-8903d6bd69ee8461 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-role-of-platelet-activation-factor-cd62p-in-the-occurrence-and-development-o-e515fa7fbf10ddd9 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/development-of-a-narrative-nursing-competency-training-programme-for-clinical-nu-ac73f915907ab6ef 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/the-effect-of-implementing-clinical-alarm-nursing-intervention-program-on-nurses-301ce50e71bf78e4 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/integrated-bioinformatics-and-clinical-validation-identify-hbegf-and-th17-marker-9714f384b8270556 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/multidisciplinary-management-of-concurrent-hypogonadism-diabetes-and-hypothyroid-59828fb4ff13e1a9 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-manifestations-and-local-inflammatory-destructive-changes-in-congenital-f286a1d265ae2332 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/pfb-03-study-protocol-diagnostic-performance-and-clinical-application-of-sup-18-18cf216d19eb1db4 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/subscription-drug-pricing-the-evidence-behind-it-comes-from-two-states-and-they-fb5a681525a81b14 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/interlocking-plate-compared-with-conventional-pin-fixation-for-undisplaced-femor-e462acf3cd6625d2 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/study-protocol-for-a-participant-and-evaluator-blinded-randomized-controlled-tri-f5fe7a8850145780 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/total-synthesis-assisted-structure-determination-and-biological-evaluation-of-cy-2e03ad678fc32f11 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/body-mass-index-related-trends-in-adverse-events-with-enfortumab-vedotin-analysi-62f4459ae59076af 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/for-health-study-protocol-for-a-randomized-controlled-feasibility-trial-of-struc-5728f033bb59ce01 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/hssynergy-scale-aware-hierarchical-attention-for-interpretable-drug-synergy-pred-738b1b5275bf9512 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/perceived-psychological-stress-is-associated-with-blood-dna-methylation-differen-26546360e66e8507 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-characteristics-surgical-pathways-and-outcomes-of-upper-tract-urothelia-0b2cc0f4b7c3d9c8 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/ldl-hypercholesterolemia-in-children-genetic-influence-and-response-to-lifestyle-ce7b949c405458cd 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/preparing-collaborative-practice-ready-graduates-an-exploration-of-practice-tuto-6e187bf07b2565c7 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/loupes-assisted-versus-conventional-orthodontic-bracket-bonding-a-split-mouth-ra-5d8b95a0486774fd 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/association-between-post-exercise-heart-rate-recovery-and-one-year-clinical-dete-09fc48a8c882f1b3 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/an-evaluation-of-a-community-based-football-for-life-ffl-programme-for-men-proto-a9a3a96d06821792 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/temporoparietal-structural-functional-coupling-abnormalities-in-drug-naive-youth-59e2b1188e53a57b 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-characteristics-and-adrenaline-use-in-anaphylaxis-in-children-a-cross-s-e0e9ca843f9d2436 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-significance-of-prenatally-diagnosed-clenched-hand-genetic-associations-f0f844e3be0e1ffe 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/timing-of-planned-birth-in-women-with-gestational-hypertension-or-pre-eclampsia-220e86b5f0bbdf5a 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/detection-of-carbapenem-resistance-mechanisms-in-difficult-to-treat-pseudomonas-20d24fbf1ce70185 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/photo-quiz-a-bloody-inoculum-yields-a-near-miss-b4a438157e8f33b1 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-implications-of-misfit-in-multiunit-implant-supported-fixed-dental-pros-3c6c672735c91015 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/correction-to-h-scp-prf-scp-bone-block-versus-sausage-technique-for-horizontal-r-1ec51d8a720e1352 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fluoride-as-a-modifier-of-metallome-homeostasis-a-systematic-review-of-animal-st-f9ed92d12befcf72 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/posttherapy-18f-fdopa-pet-findings-in-an-anaplastic-pleomorphic-xanthoastrocytom-6d7cc6b10e65372f 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/blood-pool-and-late-phase-3d-ring-czt-spect-ct-in-painful-os-peroneum-syndrome-ae1c648046114fa6 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-outcomes-of-terlipressin-using-continuous-infusion-versus-bolus-in-pati-5482d83eee4908af 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/promoting-physical-activity-in-the-context-of-clinical-care-for-people-with-hiv-5b2157f3821a2c90 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/treatment-of-shivering-during-intrapartum-cesarean-delivery-under-epidural-anest-57c6111067d38866 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/minimized-atrial-pacing-and-atrial-fibrillation-burden-in-the-danpace-ii-trial-350c940007143658 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/honey-as-a-functional-food-and-nutraceutical-bioactive-properties-health-benefit-be51a8625211aa44 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/acceptability-of-alcohol-based-hand-rub-during-neonatal-care-in-rural-ugandan-ho-a82fee9c9418b54d 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluation-of-clinical-prognostic-factors-for-radium-223-therapy-in-castration-r-deaee7bbce6c39ee 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/multikilogram-scale-process-development-for-a-key-intermediate-of-a-clinical-sta-374c9d9ee5c11a24 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/synthesis-and-self-assembly-studies-of-reusable-cholesterol-based-amphiphiles-in-c887f247fda7d9e3 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/dual-diagnosis-and-drug-related-deaths-2019-2021-an-irish-perspective-b2ae75e4f24f2627 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/risk-factors-and-ergonomic-determinants-of-low-back-pain-in-healthcare-workers-i-d3d19d8f0f0cfce8 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/correction-to-continuous-lumbar-sympathetic-blockade-enhances-the-effect-of-lumb-9ffefe0de2782043 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-outcomes-and-care-in-patients-with-posterior-glenohumeral-instability-t-75d4b1e172212738 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-outcomes-before-and-after-the-introduction-of-clazosentan-in-aneurysmal-cf2997965ba2a2ba 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/z-classification-an-anatomy-based-ridge-sinus-zygoma-classification-and-decision-4ea2c02323803c12 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/effect-of-a-sodium-fluoride-rinse-on-the-composition-of-early-oral-biofilms-form-5dee5f9feae5edf2 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/safety-and-clinical-outcomes-of-antithrombotic-therapy-in-children-and-young-adu-e73390694d25463c 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/adoption-patterns-of-anti-vascular-endothelial-growth-factor-therapies-in-retina-c75d4754e8531711 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/evaluating-the-causal-effects-of-circulating-metabolites-on-major-depression-dis-9606621b21f1facf 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/2d-4d-digit-ratio-and-brain-volumes-in-alcohol-use-disorder-935fa228c7fd1d90 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/sex-specific-differences-in-the-relationship-between-prolactin-and-glucose-metab-e4dfcecb8de4a777 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/cvs-call-for-2026-clinical-research-grants-9d5bd7bfcd23e3aa 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/connected-to-others-and-kind-to-self-social-connection-and-self-affiliation-chan-b79d4c9e0419d091 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/comparing-outcomes-using-low-dose-apixaban-and-anti-xa-monitoring-and-vitamin-k-e54ceb5fe8a7edb2 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/drug-derived-tetrahydropyrazines-for-late-stage-i-i-and-i-i-functionalization-of-076dd7bf0676aa81 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/clinical-characteristics-and-concordance-of-anti-scp-mda5-scp-antibodies-a-multi-8d86068927625843 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07805746-peri-graft-cytokine-profile-influence-of-hematologic-disease-and-don-8e6c8907448967ba 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07805655-radiofrequency-treatment-versus-topical-therapy-for-facial-acne-vulg-e105ca43bc1cdb56 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07805616-prognostic-value-of-2026-aha-acc-clinical-categorization-in-acute-pu-b6099e1cf856e5b2 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07805603-hermes-quality-and-safety-of-advanced-respiratory-support-during-pat-cf0e28e1dcd56bb5 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07805330-effects-of-blood-flow-restriction-rehabilitation-on-functional-mobil-15399895d05c5cab 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07804914-integrated-digital-health-approach-to-reduce-hazardous-alcohol-use-a-51be9f13bae0a477 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07804862-efficacy-and-safety-of-rfa-vs-mwa-for-treatment-of-large-benign-thyr-21fa1bc12fb3885f 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07804810-phase-2-clinical-study-of-mwn105-injection-in-participants-with-over-c6373971ef87bc25 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07804537-assessment-of-lung-function-lufu-at-sea-level-la-vs-high-altitude-ha-5d7862dbf016a494 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07804524-assessment-of-total-pulmonary-resistance-spap-co-between-high-altitu-4ea76c8415117dac 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07804485-assessment-of-total-pulmonary-resistance-spap-co-between-high-altitu-8ca88f6869229b5e 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07797790-real-world-patient-experiences-with-inbrija-47c7d0df8d8c143b 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07792954-a-study-to-learn-about-the-study-medicine-called-pf-08653944-taken-o-995bda1142254fa9 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07789678-epidemiological-profile-of-patients-with-idh-mutant-diffuse-gliomas-fc1a760de5691bc7 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07777419-impact-of-subthalamic-nucleus-deep-brain-stimulation-on-cognitive-an-f7491f55bffa8412 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07765888-a-study-to-learn-about-the-study-medicine-called-tilrekimig-in-peopl-67fdcd4960c94571 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07756749-minimal-access-hernia-inguinalis-treatment-of-hernia-25d81963a6899392 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07752472-pstc100-study-in-healthy-adult-subjects-93d2c9efc11a0442 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07703475-a-safety-reactogenicity-and-immunogenicity-trial-of-rvx-scpd9-booste-4dbb03ab6e6cbdd6 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07661641-a-study-of-177lu-lu-a9-0631-and-225ac-ac-a9-0642-with-68ga-ga-a9-621-c010ff9b372bbe62 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07619547-longitudinal-immunophenotyping-of-patients-with-inflammatory-bowel-d-3a796411228812d2 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07600892-pain-at-work-toolkit-definitive-trial-a9ef44442c55c3ae 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07599176-partial-stem-cell-transplant-for-sickle-cell-disease-from-matched-do-d6f5336760d056f1 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07540221-a-study-to-evaluate-the-pharmacokinetics-and-safety-of-xembify-versu-aa54aca5db95b0ce 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07468851-a-study-of-hs-10566-in-patients-with-high-risk-non-muscle-invasive-b-592b8bcc594b8559 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07468071-rollover-study-for-participants-who-have-been-treated-with-and-are-c-26f9d5b014f2d866 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07416604-a-clinical-study-to-evaluate-the-effects-of-nxt007-compared-to-emici-8beab6e252106554 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07416552-a-study-to-investigate-cea-prit-2-0-in-participants-with-metastatic-55abc7deadd2d40d 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07412002-quality-of-end-of-life-care-for-children-with-cancer-033ccf1fcd016dc6 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07361562-a-study-of-a-selective-erbb2-inhibitor-cgt4255-in-patients-with-adva-65c0b155cfb2d2fa 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07314957-impact-of-lifestyle-on-health-maintenance-a-randomized-controlled-tr-b60ef72eb6fe40b6 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07252297-the-role-of-universal-cancer-only-marker-six6-in-diagnosing-non-musc-c4220661217a96fc 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07144111-a-study-to-evaluate-the-effect-of-moderate-or-severe-hepatic-impairm-d7a8b07ae4c940d0 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07111065-fast-for-dm-fatty-acid-supplementation-trial-fast-for-dermatomyositi-ed2b3f59cab40468 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07109336-development-and-prospective-validation-of-a-heterogeneous-treatment-89264028dbc57c55 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct07066813-staging-strategies-and-their-association-with-prognosis-and-therapy-d99dee7194218280 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06968988-zanzalintinib-in-combination-with-ipilimumab-and-nivolumab-in-patien-db6e4ff8a5672fd2 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06948097-syk-inhibition-in-mitigating-lung-allograft-rejection-similar-a-tria-28f73f1ac769add4 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06717334-a-study-of-lung-cancer-screening-in-people-with-unexplained-weight-l-71cf788a91583da7 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06526338-adjuvant-ip-001-treatment-for-hcc-patients-following-surgical-resect-122f7299b94f09ee 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06414408-randomized-directly-observed-therapy-study-to-interpret-clinical-tri-9e0888b508a02045 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06364410-testing-the-combination-of-the-anticancer-drugs-trastuzumab-deruxtec-fcf362fefb5cbc8e 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06333392-total-underwater-colonoscopy-tuc-for-improved-colorectal-cancer-scre-e57f0772e54619a5 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06295679-a-study-assessing-repatha-in-combination-with-standard-of-care-soc-c-37b11ef44b4b87e9 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06274749-effects-of-urolithin-a-supplementation-on-glucose-metabolism-in-heal-597167a31fc2a3ba 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06126224-a-study-to-assess-efficacy-and-safety-of-karxt-for-the-treatment-of-6e3f8c503509bdb3 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06112613-mobile-health-for-adherence-in-breast-cancer-patients-9e2b96ceecc25d96 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct06062498-elacestrant-vs-elacestrant-plus-a-cdk4-6-inhibitor-in-patients-with-d538ed33b253c89e 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05990946-smartphone-based-remote-symptom-monitoring-to-improve-postoperative-4db774193fdb5643 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05933174-promoting-alternatives-to-sulfonylureas-to-improve-patient-safety-in-dae6234964bbe536 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05906004-post-market-clinical-follow-up-pmcf-study-of-the-pitch-patch-for-the-9b709a78e737ed2a 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05761782-engaging-diverse-and-underserved-communities-in-cancer-awareness-tra-d28f5da13afba930 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05739383-a-study-of-inclisiran-to-prevent-cardiovascular-events-in-high-risk-4e6a86c0c9fb0fdd 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05688605-a-study-of-mrg003-in-the-treatment-of-patients-with-egfr-positive-ad-850b0a572d3e373c 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct05198830-testing-the-addition-of-an-anti-cancer-drug-trc102-to-the-usual-chem-2e7a02e16da5d13c 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04815356-phase-i-study-of-anti-cd22-chimeric-receptor-t-cells-in-patients-wit-513fac2cb6d24319 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct04230356-trial-of-scheduled-versus-treatment-administration-of-donor-derived-ae1b23464ac5486e 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct02559778-pediatric-precision-laboratory-advanced-neuroblastoma-therapy-d3ed604345b907c1 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct01972919-mr-guided-phase-ii-radiotherapy-dose-escalation-in-unresectable-non-27a21a138424243b 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nct00001778-evaluation-of-patients-with-ham-tsp-0cdbd31a77066891 2026-09-04T00:00:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/gc-green-cross-receives-ind-approval-for-phase-2-3-clinical-trial-of-high-immuno-cd1bad30dd4bcc4f 2026-09-03T23:55:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/biotech-company-diatherix-plans-layoffs-d02964975bdb10a1 2026-09-03T23:32:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/up-to-20-of-children-with-dravet-syndrome-die-before-adulthood-a-long-term-study-947996a6f30c5d47 2026-09-03T23:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/big-executive-summit-lasting-impacts-on-biotech-adoption-6c3380fbbf5485a3 2026-09-03T23:21:59.000Z weekly 0.7 https://www.pharmaradar360.com/article/heartland-bioworks-tackles-indiana-s-biotech-labor-shortage-0bd50c7c15ea84ef 2026-09-03T22:57:38.000Z weekly 0.7 https://www.pharmaradar360.com/article/south-korean-biotech-licensing-deals-top-21-trillion-but-stock-prices-lag-recove-c19271ffd829b2fc 2026-09-03T22:55:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-approves-first-drug-to-treat-alexander-disease-2347a8d3e2094a59 2026-09-03T22:45:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/polyrizon-raises-4m-as-intranasal-hydrogel-biotech-taps-single-investor-263d61e403693cc9 2026-09-03T22:32:46.000Z weekly 0.7 https://www.pharmaradar360.com/article/viral-infections-biotech-ena-respiratory-inhales-3-million-from-government-fund-f0f84c97aaa50e53 2026-09-03T22:32:22.000Z weekly 0.7 https://www.pharmaradar360.com/article/biontech-vs-moderna-which-is-the-better-cancer-vaccine-stock-to-buy-now-f305da9e4bf862e7 2026-09-03T22:30:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/exclusive-ai-genomics-could-fuel-biotech-etf-re-rating-as-health-care-trades-at-e233c242c5fc5bf7 2026-09-03T22:17:42.000Z weekly 0.7 https://www.pharmaradar360.com/article/glp-1-drugs-tied-to-higher-male-pattern-hair-loss-risk-06ff0c54eff147c5 2026-09-03T22:05:00.000Z weekly 0.7 https://www.pharmaradar360.com/article/nuvectis-pharma-draws-top-biotech-funds-after-115m-raise-d3d7564b36eab305 2026-09-03T21:56:40.000Z weekly 0.7 https://www.pharmaradar360.com/article/yuce-biotech-raises-7-4m-series-b-for-single-molecule-immunodiagnostics-f5fb8efe43098828 2026-09-03T21:34:32.000Z weekly 0.7 https://www.pharmaradar360.com/article/frost-sullivan-released-the-2026-blue-book-on-the-development-of-hong-kong-stock-41de2d3846971aee 2026-09-03T21:30:04.000Z weekly 0.7 https://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-nasdaq-rare-price-target-cut-to-28-00-by-analysts-at-j-ca3688ee8f6e9d4f 2026-09-03T21:20:12.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-approves-zilganersen-injection-first-drug-for-alexander-disease-6b9acc160b21d317 2026-09-03T21:15:41.000Z weekly 0.7 https://www.pharmaradar360.com/article/eascra-biotech-expands-worcester-presence-following-8m-nasa-award-6fc2911f07faac6d 2026-09-03T20:50:15.000Z weekly 0.7 https://www.pharmaradar360.com/article/ionis-wins-fda-approval-for-first-drug-for-alexander-disease-a-rare-and-deadly-n-a7c1e1e466156811 2026-09-03T20:47:26.000Z weekly 0.7 https://www.pharmaradar360.com/article/fda-abortion-pill-challenge-delayed-until-after-midterms-e15d10d5d453a121 2026-09-03T20:46:58.000Z weekly 0.7 https://www.pharmaradar360.com/article/latigo-biotherapeutics-reports-second-quarter-2026-financial-results-and-recent-f0c7958de799160f 2026-09-03T20:24:54.000Z weekly 0.7 https://www.pharmaradar360.com/article/former-pfizer-vaccine-chief-joins-vaxcyte-trial-data-is-expected-by-october-s-en-e60f9ae456851bed 2026-09-03T20:12:25.000Z weekly 0.7